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Abstract 
Dissecting the roles of the transcriptional coactivator p300 regulating 
the oncogenic self-renewal gene NANOG 
by 
Conor Harreld Doss 
 
Chair: Anna K. Mapp 
 
Eukaryotic gene expression is controlled by the concerted actions and 
interactions of DNA-regulatory elements, transcriptional activators and 
associated coactivators.  Successful assembly of the proper activator and 
coactivators at a target gene promoter leads to the stimulation of RNA 
polymerase activity and the transcription of the gene into messenger RNA.  
Studying the interactions leading up to transcriptional initiation is challenging due 
to the relatively weak and promiscuous nature of activator-coactivator 
interactions. This dissertation documents the identification of coactivator 
functions that control the expression of the medically relevant target gene 
NANOG. 
 
	     ix 
NANOG is an embryonic transcription factor that confers tumorigenic and self-
renewing potential when expressed in human cancer cells, yet its regulation is 
poorly understood and few methods are currently available to block NANOG 
function.  We reasoned that modulating the coactivator(s) that regulate NANOG 
would allow for control over NANOG expression.  To achieve this control, we 
identified the histone acetyltransferase (HAT) p300 as a necessary and direct 
coactivator of NANOG expression in a variety of cancer cells.  
 
In order to better manipulate p300, we identified critical p300 domains involved in 
NANOG expression by systematically deleting, mutating, and inhibiting all 
potential p300 interaction surfaces and catalytic functions.  The activator-binding 
domain CH1 was found to be essential for p300-driven NANOG expression, 
suggesting the CH1 domain may act in localizing p300 to the NANOG promoter 
prior to transcription.  Additionally, p300 HAT domain activity was found to be 
necessary for maintaining high levels of histone acetylation at the NANOG 
promoter and for maintaining NANOG expression in cancer cells.  These results 
allow us to propose a model for the activator-coactivator interactions that drive 
NANOG transcription.  This model will assist in guiding future drug discovery and 
chemical probe design by providing the first validated targets capable of 
downregulating NANOG expression in cancer cells. 
 
 
 
 
 
	     1 
 
 
 
 
 
Chapter 1 
 
Regulatory targets in cancer-initiating cells and the challenges in inhibiting 
them 
 
1.1. Abstract 
Cancer-initiating cells (CICs) represent an emerging and attractive target for 
therapeutic intervention given their critical roles in tumor development and 
maintenance.  However, studying CICs in vitro is challenging due to issues with 
their identification and stability in isolation.  A variety of techniques have been 
developed to aid CIC research, including the application of small molecule 
inhibitors and probes to examine their internal functions.  Here we introduce the 
concept of CICs in cancer pathogenesis, as well as review how early small 
molecule approaches to CICs have generated meaningful insights into CIC 
biology and show great promise for future efforts to elucidate the nature of this 
elusive cell type. 
 
1.2. Cancer-initiating cells 
Cancer-initiating cells (CICs, also known as cancer stem cells) are a unique 
subpopulation of cancer cells that possess the ability to generate and maintain 
tumors (1-4).  As a result, even small populations of CICs that remain after 
conventional treatment may regenerate the tumor following therapy. CICs are 
often associated with highly drug- and radiation-resistant cancer cell populations, 
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as well metastatic cells. These observations suggest that traditional anticancer 
strategies are largely inadequate for the eradication of CICs.  Thus, new CIC-
targeting therapies are urgently needed to improve the prognosis of cancer 
patients. 
 
CICs share many features with normal stem cells such as self-renewal potential 
and the capacity to differentiate.  Unfortunately, these similarities also translate 
into difficulties in studying CICs in vitro.  First, CICs in isolation are difficult to 
maintain due to their intrinsic instability and interchangeability (5).  Second, CICs 
are poorly defined in many tumors, leading to little or even conflicting information 
regarding the actual identity of the CICs (6). Lastly, efforts to manipulate CICs in 
vitro often require complicated gene knockout or knockdown systems that can 
destroy important signaling or interaction networks that may artificially alter the 
identity of the CIC. 
 
Because of the difficulties outlined above, developing new tools for studying CICs 
has proven challenging.  In order to fully appreciate the strategies that have been 
successfully employed against CICs, it is important to first discuss some of the 
defining characteristics of CICs and how they can be exploited for CIC-targeting 
inhibitor development. 
 
The CIC hypothesis states, in essence, that cancer cells are hierarchically 
organized with a CIC at the apex driving tumor growth. (Fig. 1.1A)(1-3) When the 
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CIC divides, it can produce two general types of daughter cells. First, the CIC 
can produce a daughter cell that resembles the parental CIC (a process termed  
 
self-renewal), thereby regenerating or even expanding the pool of CICs present 
in the tumor.  Alternatively, the resulting daughter cell can exit the self-renewing 
state and differentiate into a specific, fixed identity. These non-CICs represent a 
“mature” state analogous to the post-mitotic, terminally differentiated cells found 
in normal tissues. Non-CICs possess little to no tumorigenicity, and typically 
express known markers of differentiation (Fig. 1.1B).  Since only the CICs are 
able to self-renew, the CICs are exclusively capable of generating tumorspheres 
in vitro or initiating new tumors when injected into immunocompromised mice 
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(Fig. 1B).  Together, the features of self-renewal, infinite growth, and 
differentiation status distinguish CICs from non-CICs. 
 
These defining features all have a series of underlying regulatory mechanisms 
within the cell to ensure their sustained activity.  The goal of CIC-inhibitor 
development is to first identify these mechanisms/pathways and then design 
methods to shut them down.  Recently, small molecule tools have proven to be 
effective for both the discovery and inhibition of essential CIC programs.  Here 
we will review how small molecules have advanced the study of CIC biology 
before closing with a discussion on how to identify and exploit other unique 
features of CICs including their transcriptional networks and protein-protein 
interactions. 
 
1.3. Small molecule CIC inhibitors 
In principle, the defining features of self-renewal and multipotency also represent 
the most effective means to selectively deplete CICs from a mixed cell 
population.  A CIC-targeting inhibitor can alter the cellular identity by any 
combination of three distinct effects (Fig. 1.2): 
1. Cell death: An inhibitor is acutely cytotoxic or activates apoptosis in CICs 
2. Growth arrest/senescence: The small molecule slows or ceases CIC cell 
cycle progression, thereby halting self-renewal and growth 
3. Differentiation: Small molecule treatment causes the CICs to change 
and/or commit to a particular cell lineage, thereby exiting the CIC state 
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A number of small molecules have been reported to selectively affect CICs 
(Table 1.1).  Most frequently, these compounds target key signaling enzymes 
that regulate CIC maintenance such as PI3K/mTOR and γ−secretase that 
regulate CIC maintenance but, as will be discussed below, these are not the only 
possible targets.  In fact, several of the most successful CIC inhibitors discovered 
to date act via unknown mechanisms.  Identifying the potential mechanisms in 
these cases can provide highly illuminating insights into CIC biology and thereby 
inform inhibitor design in the future. 
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1.3.1 CIC inhibitors with known targets 
Conventional CIC inhibitor development follows the reverse chemical genetics 
approach wherein a cellular protein is first identified as relevant for CIC 
regulation, and inhibitors are chosen or designed to block the function of that 
protein.  For example, Lonardo et al. (7), found that the Nodal signaling pathway 
was found to be a driver of self-renewal in pancreatic CICs through a series of 
knockdown experiments silencing either the Nodal ligand or its receptor, ALK4.  
Pharmacological inhibition of ALK4 by the compound SB431542 (Fig. 1.3A) 
dose-dependently suppressed CIC-driven tumorsphere formation and blocked 
Nodal-enhanced growth.  In contrast, the ALK5 antagonist LY2157299 had no 
effect on tumorsphere formation, indicating that a distinct set of TGFβ receptors 
may be responsible of pancreatic CIC maintenance. 	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TABLE 1: CIC-Selective Inhibitors
Biological Pathway
Target
Compound
In vitro IC50 (nM)
Effects
References
Notch
γ-secretase
DAPT
~20
Blocks the response of Nestin+ GBM CICs to hypoxia; reduces the fraction of CD44+/CD24- breast CICs in cell lines;
41-46
GSI-18
~50
Depleted CD133+ GBM CIC fraction; reduces neurosphere formation and promotes differentiation in vitro
49-51
RO4929097
~4.0
Reduces melanoma CIC potential
52
DBZ
1.0-2.0
Suppresses Bcl-2 expression in prostate CICs and restores docetaxel sensitivity when combined with Hh inhibitors
53
L685485
54
MRK-003
~0.5
Irreversibly inhibits CICs mammosphere formation, reduces CIC frequency, and induces differentiation in a mouse Her2 model;
55-59
TGFβ/SMAD
ALK4/7
SB431542
90-100
Reduces the fraction of CD49f+/CD61+ breast CICs and reversed EMT phenotypes; Dose-dependently inhibits pancreatic CIC tumorsphere formation; reverses pancreatic CIC enrichment following gemcitabine treatment
7, 60
ALK5
A-83-01
10-15
Reduces the fraction of CD49f+/CD61+ breast CICs and reversed EMT phenotypes
60
LY2109761
30-40  for TßRI; ~300 for TßRII
Restored an epithelial phenotype to CD44+ breast CICs 
61
Hedgehog
SMO
Cyclopamine
40-50
Reduces AML CIC self-renewal in vitro; blocks AKT activation in prostate CICs and restores docetaxel sensitivity in combination with Notch inhibitors
44,57,62-66
GDC-0449
~3
Blocks AKT activation in prostate CICs and restores doceetaxel sensitivity in combination with Notch inhibitors66
IPI-926
5.0-9.0
Reduces AML CIC self-renewal in vitro and in vivo
63,67
JAK/STAT
STAT3
S31-201
80,000-90,000
Inhibits expression of the NANOG self-renewal gene in hepatocellular CICs; prevents neurosphere growth in GBM CICs; depletes GBM CIC marker expression
10, 68
FLLL32
1,000-5,000
Reduced viability and tumorsphere formation in colon CICs
69
WP1066
~2,500
Inhibits the hypoxia response in Nestin+ GBM CICs
42
STA-21
10,000-20,000
Prevents neurosphere growth in GBM CICs; depletes GBM CIC marker expression
68
Stattic
4,300-5,900
Induced apoptosis in GBM CICs
70
JAK2
NVP-BSK805
 ~0.5
Reduced breast CIC number in established xenografts
71
RTK/PI3K
PI3K/mTOR
LY294002
500-1,000 
Inhibits CIC survival in pancreatic and breast cancer cell lines; restores drug sensitivity in GBM CICs
18, 72, 73
NVP-BEZ235
5-70
Inhibits CIC survival in pancreatic cell lines; induces GBM CIC differentiation
72, 74, 75
FKBP12/mTORC1
Rapamycin
~1.0
Inhibits CIC survival in breast cancer cell lines; restores drug sensitivity?; Blocks the hypoxia response in Nestin+ GBM CICs
18, 42, 73
MAPK
MEK1/2
U0126
~60
Synergizes with FTIs to induce CML CIC apoptosis;
74-79
SL327
150-250
Induces GBM CIC differentiation
74, 75, 77
PD184352
~17
Inhibits breast CIC self-renewal in vitro; synergizes with FTIs to induce CML CIC apoptosis
79, 80
ERK1/2
PD98059
~2000
Blocks the response of Nestin+ GBM CICs to hypoxia;
18
Histone modifications
HDAC class I
Trichostatin A
1.0-2.0
Reduces ALDH1+, CD133+ GBM neurosphere-derived cells
33
LBH589
5.0-20
Eliminates CML CICs when combined with imatinib
34
SAHA
81, 82
MS-275
5.0-20
Reduces ALDH1+, CD133+ GBM neurosphere-derived cells
33
LSD1
Tranylcypromine
~2.0
Induces AML CIC differentiation in vitro, depletes CIC population in vivo
36
Wnt/β-catenin
???
Salinomycin
Reduces CIC fraction in breast and CLL cell lines
5, 12, 15-17
NF-κB
???
Parthenolide
Selectively induces apoptosis and ROS production in AML CICs
83, 84
Dopamine receptors
DR
Thioridazine
Ki = 5-10 nM
Induces AML CIC differentiation and granulocytic maturation
25
DNA Repair
CHK1/2
SB218078
~15
Reduces the CD133+ colon CIC fraction; increases cytotoxicity due to DNA damage in lung CICs
85, 86
AZD7762
5-10
Restores lung CIC sensitivity to chemotherapeutics in vivo
85
DBH
3,000-3,500
Restores GBM CIC sensitivity to ionizing radiation
87
CHK1
UCN-01
~25
Reduces the CD133+ colon CIC fraction
86
Leukotriene biosynthesisALOX5
Zileuton
400-900
Blocks CML CIC maturation into malignant leukemia cells
88
Lipidation
Farnesyltransferase
BMS-214662
1,300-1,400
Induces apoptosis in quiescent CML CICs
79, 89
Nuclear receptors
PPARγ
Ciglitazone
Inhibited GBM CIC growth and modulated expression of stemness genes
91
15-deoxy-∆12,14-prostaglandinJ2
Inhibited GBM CIC growth and modulated expression of stemness genes
91
Telomerase
hTERT
imetelstat
92
Wnt/ß-catenin
???
Sulforaphane
93
???
Curcumin
94, 95
CXCR1
Repertaxin
96
Metformin
97, 98
Translation
Ribosome
omacetaxine
Induces apoptosis in primitive CML CICs
99
Abbreviations: FTI (farnesyltransferase inhibitor); CML (chronic myeloid leukemia); CLL (chronic lymphoid leukemia); AML (acute myeloid leukemia); GBM (glioblastoma multiforme); EMT (epithelial-mesenchymal transition)
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This type of reverse chemical genetics approach has also been applied to other 
known oncogenes such as STAT3.  Constitutive JAK/STAT3 signaling is 
frequently observed in various cancers and relies upon tyrosine phosphorylation 
to recruit and activate the transcription factor STAT3 (8).  STAT3 recognizes 
phosphotyrosine residues via its SH2 domain, and numerous small molecules 
have been developed as competitive SH2 ligands (9).  When STAT3 was later 
identified as a CIC-relevant target, those same SH2 inhibitors demonstrated anti-
CIC activity.  For instance, the compound S31-201 was shown to deplete CICs in 
hepatocellular carcinoma cell lines, in part by downregulating the stem cell self-
renewal NANOG (10).  The observation that STAT3 signaling could drive 
NANOG expression in somatic tissues like liver cells suggests that one 
oncogenic role for STAT3 may be establishing embryonic self-renewal programs 
in CICs.  These cells thus adopt a less mature, more stem-like phenotype and 
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become freed from extrinsic homeostatic signals, helping to accelerate tumor 
progression. 
 
These studies highlight how CIC inhibitors can aid in validating other discoveries 
in CIC biology.  However, the study of CICs has also benefitted from the use of 
so-called “orphan” CIC inhibitors, compounds that as of yet have no clear 
intracellular targets.  Delineating the mechanisms by which these orphan 
inhibitors affect CICs could reveal novel details of CIC generation and 
maintenance. 
 
1.3.2 CIC inhibitors without known targets 
Forward chemical genetic screens identifying compounds that selectively kill 
CICs by conventional high-throughput assays have proven technically difficult 
due to the low frequency, high heterogeneity, and instability of CICs in vitro. To 
overcome these limitations, Gupta et al. (5) generated an artificially enriched CIC 
population by inducing an epithelial-to-mesenchymal transition (EMT) cell 
phenotype. EMT is an evolutionarily conserved developmental process 
associated with cellular migration and invasiveness, as well as the acquisition of 
stem-like properties in cancer cells (11). Stable knockdown of the epithelial 
marker E-cadherin induced EMT and greatly enriched for the putative 
CD44+/CD24lo breast CIC population. These induced-EMT cells were stable 
enough to serve as a screening platform for compounds exhibiting selective 
cytotoxicity compared to the uninduced parental cells (5). Using a commercially 
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available library, 32 compounds were identified as hits showing modest 
selectivity for the transdifferentiated cells, including the natural product 
salinomycin (Fig. 1.3B; Table 1). Salinomycin treatment alone depleted the 
CD44+/CD24lo fraction and strongly inhibited tumor engraftment in a mouse 
xenograft model. Most strikingly, salinomycin also proved effective against 
established tumors in mice, inducing both cancer cell differentiation and death, 
suggesting that salinomycin could target and eliminate the CIC subpopulation in 
vivo. 
 
Salinomycin is a highly selective potassium ionophore, suggesting that Na+/K+ 
ion gradients may be finely balanced in CICs. In support of this hypothesis, 
another polyether potassium ionophore, nigericin, was reported to target breast 
CICs (5) and possess similar anticancer effects as salinomycin (12, 13). 
 
Salinomycin has been used for decades as a veterinary antibiotic.  However, its 
activity against human CICs was unexpected.  Subsequent studies have 
demonstrated broad anti-CIC activity, targeting the cancer-initiating populations 
in cancers of the breast (5), lung (14), stomach (15), and bone (16), as well as in 
chronic myelogenous leukemia (17)(Table 1).  In addition to its activity as a 
cation chelator, salinomycin has also been reported to inhibit the ABC family of 
multidrug transporters that are frequently upregulated in CICs (17-20). This 
activity could account for the increased sensitivity of the putative CICs to 
conventional chemotherapeutics in the presence of salinomycin (15-17). 
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However such observations do not explain why salinomycin alone displays CIC-
selective toxicity. 
 
The general activity of salinomycin against such physiologically diverse tumors 
may suggest that CICs all possess some common target essential for their self-
renewal and survival.  Lu et al. (12) saw that in primary CLL cells, salinomycin 
downregulated components of the Wnt/β-catenin signaling pathway, a 
developmental pathway frequently associated with stem cell and CIC self-
renewal (21). Salinomycin has also been show to inhibit GSK3β phosphorylation 
and β-catenin accumulation in osteosarcoma cells, further supporting the idea 
that Wnt/β-catenin may be the intracellular target (16). Unfortunately, there are 
few Wnt pathway inhibitors currently available, with active small molecules only 
recently being reported (22). Better resolution of salinomycin’s mechanism of 
action will require further experiments to determine whether, in fact, Wnt 
signaling inhibition is the main activity against CICs, or if there are indirect effects 
like oxidative or metabolic stress that are not coupled with Wnt downregulation 
(23). 
 
Most discovery and screening efforts with CICs suffer due to a lack of robust in 
vitro models.  Gupta et al. (5) created an artificial EMT assay that allowed them 
to identify salinomycin as an inhibitor of EMT-dependent processes in CICs.  
However, CICs can also be defined by other phenotypes such as the expression 
of undifferentiated markers and resistance to differentiation. Bhatia and 
	     12 
colleagues (24) generated a neoplastic varianthuman ESCs (v-hESC) that 
recapitulate many features of CICs including high tumorigenicity, enhanced self-
renewal, and impaired differentiation potential.  These v-hESCs were stable 
enough in vitro to allow for high-throughput screening for compounds capable of 
inducing differentiation (25). 
 
Unexpectedly, the dopamine receptor (DR) antagonist and antipsychotic drug 
thioridazine was found to induce v-hESC differentiation (Fig. 1.3C; Table 1). 
Furthermore, racemic thioridazine reduced the CIC fraction in primary AML cells 
and increased the expression of mature granulocytic markers, suggesting that 
thioridazine is capable of inducing differentiation in a therapeutically relevant 
AML disease model. More importantly, however, thioridazine had no effect on the 
differentiation of umbilical cord HSCs, indicating a selective effect on the cancer 
cells.  Salinomycin, the previous standard for CIC-targeting small molecules, 
proved cytotoxic to both HSCs and AML CICs. 
 
The discovery of a CIC-selective DR antagonist prompted an investigation into 
the possible role of DR signaling in AML CICs. Sachlos et al. (25) found that AML 
blasts frequently expressed all 5 DR subtypes, and that high DR levels 
overlapped and correlated with the CIC populations.  The enantiomers of 
thioridazine display between 2-10-fold differences in DR subtype selectivity (26), 
leading to potential questions about the relevant receptor targets.  More 
importantly, the DR subtypes can have opposing signaling effects, with D1 and D5 
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stimulating intracellular cAMP production while D2, D3, and D4 directly repress 
cAMP production.  To clarify the mechanism of thioridazine in CICs, Sachlos et 
al. (25) also tested family-specific DR ligands.  The D1/D5 antagonist SKF-38,393 
blocked AML proliferation, while the D2 agonist 7OH-DPAT actually promoted 
AML cell growth.  These results suggest that shutting down the DR-mediated 
production of cAMP may be an effective way of inhibiting AML CIC self-renewal. 
 
As a chemical probe, thioridazine suffers due to a low level of receptor selectivity.  
In addition to DR, thioridazine and related phenothiazines have been reported to 
affect various other intracellular targets such as AKT and MALT1 (27, 28).  
Furthermore, the effective CIC-targeting concentrations were much greater than 
the typical Ki for DR (1 nM vs. 1 µM; Table 1), possibly indicating a role for 
additional off-target effects of thioridazine. 
 
From a clinical standpoint, however, these results were encouraging.  
Thioridazine and other DR antagonists are already FDA-approved and have 
been prescribed for schizophrenic patients for years, but their effects on CIC 
populations had never been examined.  Further work will be needed to delineate 
the role of DR in CICs, as well as determining whether gain of DR function is a 
transformative (early) or self-reinforcing (late) step in tumor development and 
progression.  Remarkably, patients receiving DR antagonist medications have 
reduced incidences of cancer relative to the general population (29), suggesting 
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that DR antagonism may well be prophylactic in regards to disease prevention 
and recurrence. 
 
1.4. Unaddressed targets in CIC biology 
As the studies described above illustrate, small molecule inhibitors have proven 
successful in selectively blocking crucial functions.  However, these studies are 
also biased towards signaling pathways and catalytic activities that are 
components of larger, interconnected regulatory networks in CICs (Table 1.1).  
CICs undoubtedly rely upon multiple internal and external forms of regulation to 
maintain their identity and self-renewal, and thus there are other potential 
avenues to explore modulating CIC behavior. 
 
For example, one of the central cell-autonomous regulatory networks in CICs is 
their unique transcriptional and gene expression profile (30-32).  A number of 
CIC-selective inhibitors target transcriptional coregulatory proteins such as 
histone deacetylases (33-35) or lysine-specific demethylase 1 (LSD1) (36).  
These compounds impair CIC growth and self-renewal, however their 
mechanisms remain unclear.  CIC-associated gene networks such as the ESC-
like, NANOG-driven network (31, 37, 38) are fundamental to CIC identity and 
therefore represent potential targets for new modulatory strategies.  However, 
these networks operate through protein-protein interactions (PPI) and to date no 
PPI inhibitors have been pursued as CIC-targeting probes. 
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The dearth of PPI inhibitors in use for studying CICs originates, in part, due to 
relatively limited information available regarding the PPIs taking place in CICs.  
PPIs between transcription factors and coregulatory proteins are often weak 
(low-micromolar affinities) and mediated via intrinsically disordered domains (39, 
40) that hinder structural characterization.  Furthermore, transcriptional 
regulatory proteins can engage in a variety of multivalent and/or cooperative 
interactions depending on gene context, thereby creating a large number of 
possible interactions researchers must consider when attempting to probe CIC 
regulatory networks. 
 
These challenges are not insurmountable however, and we view PPIs in CIC 
biology as a ripe and currently under-explored field.  The work presented in this 
thesis focuses on our efforts to advance the identification and modulation of PPIs 
in CIC transcriptional networks, particularly through coactivator proteins essential 
for driving self-renewal genes in cancer.   
 
1.5. Research goals 
One of the goals of this research is to identify essential activators and 
coactivators of self-renewal genes when little is known about the causes of 
aberrant gene expression.  Specifically, we present our analysis of the 
coactivator protein p300 and its role in driving expression of the self-renewal 
gene NANOG. We show in Chapter 2 a reasonable method to narrow down a list 
of candidate activators and coactivators, and demonstrate how the hypotheses 
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generated can be systematically tested and confirmed.  The second challenge in 
studying multidomain coactivator proteins is dissecting the relevant functions 
within the protein and producing a clearer picture of how proteins interact with 
each other and in what order. 
 
A second goal is to generate a molecular-level picture of how activators and 
coactivators interact and cooperate to drive NANOG expression.  In Chapter 3 
we present a systematic analysis of p300 and show how a combination of 
mutagenesis and small molecule studies identify two crucial domains for p300-
mediated NANOG expression.  This information allows us to form a more 
detailed model of how transcriptional complexes are assembled at the NANOG 
promoter.  The results and methods present in this thesis thus aid the study of 
CICs by identifying several new targets for small molecule and potential drug 
design.  However, CIC biology still possesses several technical challenges that 
require the development of new tools.  These challenges and potential ways to 
overcome them are discussed in Chapter 4. 
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Chapter 2 
Investigating the essential activators and coactivators for NANOG 
expression in cancer 
2.1. Abstract 
Eukaryotic gene transcription relies upon the concerted actions and interactions 
of activator and coactivator proteins.  The multiprotein complexes that regulate 
transcription can be gene-specific and therefore represent an opportunity for 
selective modulation of target gene expression.  Unfortunately, the regulatory 
proteins for many genes are unknown.  Here we describe the identification of the 
coactivator p300 as direct and essential regulator of the embryonic transcription 
factor NANOG in human cancer cells.  Aberrant NANOG expression promotes 
tumorigenesis and confers self-renewal and drug-resistance, yet no methods are 
currently available to inhibit NANOG.  Our results indicate that loss of p300 
function attenuates both NANOG expression and NANOG-dependent 
phenotypes, suggesting that p300 may be a viable target for inhibiting NANOG.  
We further show that the Kruppel-like factor (KLF) family of transcriptional 
activators, in particular KLF4, is required for NANOG expression, revealing yet 
another potential target for NANOG inhibition.  These findings help generate a 
clearer picture of the activator-coactivator complexes regulating NANOG and can 
be used to design new ways of modulating NANOG expression in cancer. 
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2.2. Transcriptional coactivators and gene expression 
Eukaryotic gene activation is regulated through the sequential interactions of a 
large number of modulatory multiprotein complexes involving both transcriptional 
activators and coregulatory proteins termed coactivators (1).  Transcriptional 
activators bind to specific cognate sequences in the promoter and enhancer 
regions of genes and, once localized to the DNA, stimulate transcription by 
bringing the basal transcriptional machinery to the transcriptional initiation site 
(2).  While some activators are able to directly recruit general factors such as 
TFIID and RNA polymerase II, most activators rely on coactivators to facilitate 
gene activation.  The resulting multiprotein complexes perform such diverse 
functions as remodeling the chromatin, stabilizing the transcriptional preinitiation 
complex, and even conferring temporal- and cell-type selectivity in which genes 
are expressed in the cell (3-5).  As a result, it is imperative to understand the 
series of protein-protein interactions (PPI) and catalytic functions between 
transcriptional components in order to fully understand how complex biological 
programs are regulated. 
 
The need for a detailed understanding of gene regulatory mechanisms becomes 
especially important when trying to modulate gene expression.  A number of 
human diseases manifest as a result of aberrant gene activation, including 
cancer, developmental defects, and metabolic disorders (6-9).  In the case of 
cancer, numerous groups have attempted to modulate transcription in order to 
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treat the disease through the use of coactivator enzymatic inhibitors as well as 
PPI inhibitors (10-13).  However, the design and implementation of these 
strategies requires knowledge about both identity of the activators/coactivators 
involved in expression of a target gene and the nature of the PPIs that underlie 
the regulatory complexes.  Unfortunately, this level of information is often lacking 
for many disease-related genes.  We have set out to identify key coactivators 
and PPIs essential for the expression of one such cancer-associated gene, 
NANOG.  We found that the coactivator p300, in particular, is an important and 
direct regulator of NANOG expression in two different carcinoma cell lines, and 
provide preliminary evidence for how p300 is initially recruited to the NANOG 
promoter.  This information provides the foundation for designing new inhibition 
strategies to downregulate NANOG and reverse aggressive, NANOG-dependent 
cancer phenotypes. 
 
2.2.1. The role of NANOG in cancer 
NANOG is an embryonic transcription factor that has recently been implicated as 
a driver of several human malignancies, including head and neck squamous cell 
carcinoma (HNSCC), prostate carcinoma, glioblastoma, and germ cell tumors 
(14-17).  Elevated NANOG levels are associated with poor survival in HNSCC 
patients (17), resistance to standard chemotherapeutics (18), and interestingly, 
increased features of cancer-initiating cells (CICs) (19, 20).  These CICs exhibit 
complex phenotypes such as self-renewal, sustained multipotency, 
tumorigenicity, and a gene expression profile similar to that found in embryonic 
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stem cells (ESCs) (14, 15, 21).  Moreover, downregulation of NANOG in cancer 
cells markedly decreases these malignant features, consistent with the idea that 
NANOG is a core factor in a complex CIC transcriptional program.  We therefore 
hypothesized that loss of function of key coactivators that regulate NANOG 
would disrupt both NANOG expression and NANOG-dependent phenotypes.  To 
test this hypothesis though, we must first examine the known coregulators of 
NANOG in order to narrow down our search for potential targets. 
 
2.2.2. Coregulators of NANOG expression 
Interactome studies of NANOG have revealed an extended network of protein-
protein interactions that participate in both regulating the pluripotency gene 
network, as well as NANOG itself (22, 23).  For example, the Baf (Brg/Brahma-
associated factor) ATP-dependent chromatin remodeling complexes are 
essential for formation of the pluripotent cells of the early embryo.  ESCs 
deficient in the core Brg enzyme maintain the expression of Oct4, Sox2, and 
Nanog for several divisions but ultimately lose self-renewal capacity and 
downregulate pluripotency marker expression suggesting that Brg is required to 
maintain stable expression of Oct4 and Nanog over time (4, 5).  Baf complexes in 
ESCs (esBaf) include Brg, Baf155 and Baf250A.  Brg and Baf155 have been 
reported to bind extensively to ESC regulator genes, including Oct4, Sox2, 
Nanog, and Myc, whereas Brg localizes to Klf4.  The essential nature of esBaf 
complexes and their localization within the genome suggest that esBaf are critical 
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for ESC self-renewal and pluripotency by directly regulating the core 
transcriptional circuitry (4, 5). 
 
Several other coactivators have been reported to regulate the pluripotency 
network in ESCs, including Mediator (24), the histone acetyltransferase p300 
(25), and surprisingly a nucleotide base-excision repair (NER) complex (26).  
Using defined in vitro transcription assay, Fong et al. (26) screened for cofactors 
required for OCT4/SOX2-mediated activation from the Nanog promoter.  
Unexpectedly, the XPC-RAD23B-CETN2 NER complex was found to be a 
necessary coactivator for both in vitro and in vivo transcription of Nanog.  Mouse 
ESCs depleted of XPC showed decreased Nanog expression, reduced self-
renewal capacity, and increased differentiation, indicating that the NER complex 
is essential for maintaining Nanog expression driven by Oct4/Sox2. 
 
Interestingly, the activators OCT4 and NANOG have also been shown to interact 
with several corepressor proteins including members of the histone deacetylase 
NuRD complex (P66β, Sall4 and HDAC2) and polycomb proteins (YY1, Rnf2 and 
Rybp) (22, 27).  These corepressor complexes are generally though to aid in 
suppressing lineage-specific genes and thereby maintain OCT4 and NANOG 
expression and self-renewal, however some positive regulatory roles have been 
reported.  For example, the mSin3A-HDAC complex directly stimulates Nanog 
expression in mouse ESCs (27).  Knockdown of mSin3A-HDAC components or 
HDAC inhibitor treatment reduces Nanog expression, whereas overexpression of 
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mSin3A-HDAC subunits increases Nanog expression.  Interestingly, mSin3A-
HDAC occupancy at the Nanog promoter does not result in histone 
deacetylation, indicating that HDAC activity is required for Nanog expression but 
is not histone-mediated. 
 
There appears to be a strong correlation between histone acetylation and the 
core pluripotency transcriptional network. In particular, the histone 
acetyltransferase p300 plays a prominent role in regulating pluripotency.  Mouse 
ESCs lacking p300 display abnormal gene marker expression and aberrant 
differentiation, as well as reduced expression of Nanog (28).  Forced expression 
of Nanog rescues these defects, indicating that p300 may be an upstream 
regulator of Nanog expression.  In support of this, global-binding studies have 
found that p300 colocalizes with the core transcription factors Oct4, Sox2, and 
Nanog at active pluripotency-associated genes (25).  These observations led us 
to test if p300 has an important role in NANOG regulation in cancer and cancer-
initiating cells.   
 
2.3. The coactivator p300 is essential for NANOG expression and 
function 
 
2.3.1. Loss of p300 attenuates NANOG-dependent phenotypes in HNSCC  
The ESC transcriptional program is regulated by a complex network of activators 
and cofactors yet thus far only a few coactivators have been suggested to 
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contribute (21, 25).  Among these coactivators, the histone acetyltransferase 
p300 has been reported to regulate self-renewal and cellular identity (25, 28, 29).  
Given these observations, we hypothesized that p300 may also be an essential 
coactivator for NANOG expression in cancer cells. 
 
NANOG is commonly expressed in head and neck squamous cell carcinomas 
(HNSCC) and is associated with aggressive phenotypes such as invasiveness 
and CIC populations (17, 18, 30).  To begin testing whether p300 is a necessary 
coactivator for oncogenic NANOG expression, the Pan laboratory (Ohio State 
University) generated stable p300-deficient clones in the HNSCC model cell line 
UMSCC74A.  UMSCC74A-scramble control cells expressed high levels of 
NANOG (Fig. 2.1A), consistent with other HNSCC lines (17).  However, 
knockdown of p300 resulted in a strong reduction in NANOG levels (Fig. 2.1A), 
suggesting p300 is important in sustaining high NANOG levels. 
 
We next examined what impact the loss of p300 would have on NANOG-
dependent phenotypes.  When expressed in human cancers, NANOG confers 
stem cell-like features including greater metastatic potential and self-renewing 
capacity (20).  In vitro, these properties can be assessed using wound healing 
and tumorsphere formation assays, respectively.  When the cells lose NANOG or 
stem like-character, they are expected to exhibit reduced wound healing and 
motility, as well as a reduced ability to self-renew and generate tumorspheres 
when cultured under nonadherent condtions. When we examined p300-deficient 
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UMSCC74A cells, we found that the knockdown cells showed greatly reduced 
motility in wound healing assays, closing ~20% of the wound in the time control 
cells take  
 
 
to fully seal reform a monolayer (Fig. 2.1B).  p300 knockdown also dramatically 
inhibited the ability of UMSCC74A cells to form tumorspheres in suspension 
culture (Fig. 4.2C), suggesting that p300 loss reduced the ability of UMSCC74A 
cells to self-renew.  These results indicated that p300 is important for NANOG 
expression and NANOG-driven cancer phenotypes in HNSCC cells. 
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2.3.2. Loss of p300 downregulates NANOG expression in pluripotent NCCIT 
cells 
We then sought to explore whether p300 is necessary for NANOG expression in 
other cancers besides HNSCC using similar loss-of-function knockdown studies.  
The teratocarcinoma cell line NCCIT is pluripotent and endogenously expresses  
 
NANOG and other components of the ESC transcriptional network (31, 32).  
Transient transfection of NCCIT cells with shRNAs against NANOG, p300, or the 
p300-paralog CBP all downregulated their targets (Fig. 2.2A).  Interestingly, 
p300-knockdown also inhibited NANOG expression, consistent with the results 
seen in HNSCC cells.  In contrast, loss of the coactivator CBP had no significant 
impact on NANOG levels, even though CBP and p300 are similar and thought to 
be largely functionally redundant (9).  In support of this, p300-knockdown caused 
an increase in CBP levels, suggesting that CBP was upregulated to compensate 
for loss of a redundant protein.  However, even elevated CBP levels are 
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insufficient to maintain NANOG expression, suggesting that CBP and p300 may 
have differential roles in regulating NANOG. 
 
Taken together these results indicate that p300 function is essential for NANOG 
expression in both HNSCC and pluripotent cancer cells, two physiologically and 
etiologically distinct tumor types.  These observations therefore suggest that 
p300 may be a conserved cofactor for NANOG expression and thus a potential 
target for targeting across the spectrum of NANOG-dependent tumors. 
 
2.4.  Determination of the genomic origin of NANOG in cancer cells 
Our results in the loss of p300 function studies suggest that p300 may be an 
important regulator of NANOG expression in cancer cells.  However, those 
experiments did not assess whether p300 functions as a direct or indirect 
regulator of the NANOG gene.  p300 could very well be required for expression 
of an upstream regulator of NANOG, and thus knockdown or inhibition of p300 
would affect NANOG expression through an intermediary gene product.  Such a 
scenario would require identifying the intermediate(s) and likely shift the focus of 
the experiments away from NANOG. 
 
Further complicating the system is the fact that NANOG transcripts in several 
cancer cell lines have been reported to originate from the NANOGP8 
pseudogene located on chromosome 15 (15, 33-36) instead of the NANOG1 
locus associated with embryonic expression. 
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We reasoned that, if p300 acted as a direct regulator of NANOG, it would be 
localized to the NANOG proximal promoter consistent with other direct, p300-
dependent genes (37).  We therefore set out to determine whether p300 is bound 
to the NANOG1 and/or NANOGP8 promoters in human cancer cell lines. 
 
 
Chromatin immunoprecipitation (ChIP) assays were conducted first in the 
pluripotent embryonal carcinoma NCCIT cells.  In this experiment, NCCIT cells 
were fixed with formaldehyde and chromatin-bound proteins like histone H3 and 
p300 were immunoprecipitated to pull-down associated sequences of DNA that 
can be amplified using sequence-specific PCR primers.  Given the two potential 
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sources of NANOG mRNA in human cancers, two gene-specific primer sets were 
designed: one for the NANOG1 proximal promoter, and one for the analogous 5’ 
region of NANOGP8 (Fig. 2.3A). 
 
Immunoprecipitation for p300 revealed ~9-fold enrichment for DNA from the 
NANOG1 promoter over beads alone (Fig. 2.3B), indicating that the p300 
coactivator is directly associating with the NANOG1 locus and likely engaged 
with transcriptional machinery driving expression from that gene.  In contrast, 
p300 failed to show significant enrichment over background at the NANOGP8 
promoter.  Histone H3 was localized consistently across both loci, showing that 
chromatin fragments from NANOGP8 can be recovered and therefore the 
absence of p300 at NANOGP8 is not due to differences in PCR primers or 
amplification efficiency.  We also examined the presence of p300-associated 
histone acetylation, notably histone H3 acetylation (H3Kac), at both loci.  H3Kac 
was observed to be significantly enriched at the NANOG1 locus relative to the 
bead control, consistent with acetylation patterns at actively transcribed genes.  
H3Kac was also observed at the NANOGP8 locus but at ~50% of the NANOG1 
levels.  H3Kac is a common histone modification and its presence at NANOGP8 
may be the result of global acetylation by HAT enzymes other than p300.  Thus, 
even if NANOGP8 contributes to overall NANOG expression in NCCIT cells, 
p300 does not appear to directly regulate NANOGP8.  Moreover, loss of p300 
function has a significant inhibitory effect NANOG expression levels, indicating 
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that NANOGP8 has only a minor, if any, contribution to overall NANOG 
expression in NCCIT cells. 
 
Taken together, these data indicate that the NANOG1 locus is the primary source 
of NANOG mRNA and protein in NCCIT cells, and that the pseudogene 
NANOGP8 is not actively transcribed.   In support of this, the transcriptional 
coactivator shows significant localization to the NANOG1 proximal promoter and 
no detectable association with the NANOGP8 upstream region.  Furthermore, the 
NANOG1 promoter shows high levels of histone H3 acetylation (H3Kac) 
modification (Fig. 2.3B), a general marker for p300 HAT activity and actively 
transcribed genes.  In contrast, the NANOGP8 upstream region is relatively 
depleted of H3Kac modifications, consistent with NANOGP8 being 
transcriptionally silent.  p300 thus appears to be both a direct and essential 
regulator of the NANOG1 promoter, and we elected to focus on how p300 may 
be recruited to this sequence of DNA. 
 
2.5. NANOG1 promoter analysis reveals a pair of key KLF motifs 
2.5.1. Deletion screening 
Significant effort has been invested in studying the transcriptional activators 
involved in driving NANOG expression in embryonic stem cells (see above), yet 
few activators and even fewer coactivators have been identified in cancer cells.  
Having identified p300 as a direct regulator of NANOG, we next sought to identify 
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potential activator proteins that could bind p300 and recruit it to the NANOG 
promoter. 
 
The NANOG1 proximal promoter is loosely defined as spanning from –380 bp to 
+24 bp from the transcriptional start site.  This region contains consensus motifs 
for many activators and repressors involved in the complicated transcriptional 
regulation of NANOG.  We hypothesized that p300 could be recruited to the 
NANOG promoter by binding to one or more of these proteins, however it was 
not clear what transcription factor(s) would be responsible in cancer cells.  
Running the promoter sequence through Genomatix MatInspector predicts 115 
different transcription factor-binding sites, roughly 1 site every 4 nucleotides ().  
Several of the predicted motifs match known NANOG regulators in ESCs, such 
as OCT4/SOX2, KLF4, and NANOG itself (Table 2.1).  Additionally, several 
known oncogenes were predicted to bind including GLI, c-Jun, ETS, and SMAD4 
(38). 
	     38 
 
 
 
Table 2.1. Genomatix predictions in the NANOG proximal promoter
Predicted protein Start End Strand P
Cell cycle regulators: Cell cycle homology element 15 9 (-) 0.956 gagtTTGAaacca
cAMP-responsive element binding proteins 31 21 (+) 0.997 aactccTGACttcaggtgatc
Human and murine ETS1 factors 32 22 (-) 0.847 ggatcaCCTGaagtcaggagt
Sterol regulatory element binding proteins 32 25 (-) 0.944 ggaTCACctgaagtc
Two-handed zinc finger homeodomain transcription factors 32 26 (-) 0.991 ggatcACCTgaag
Myoblast determining factors 43 35 (-) 0.883 ccgtGGCAggcggatca
HIF-1 ancillary sequence family 46 41 (+) 0.934 tgcCACGgcct
GLI zinc finger family 54 47 (+) 0.864 acggCCTCccaattt
SOX/SRY-sex/testis determinig and related HMG box factors 64 52 (-) 0.888 taatcccagtaAATTgggaggccgt
AT rich interactive domain factor 66 56 (+) 0.926 tcccaaTTTActgggattaca
Abdominal-B type homeodomain transcription factors 64 56 (-) 0.917 taatcccagTAAAttgg
Bicoid-like homeodomain transcription factors 69 61 (-) 0.933 ccctgtAATCccagtaa
Brn POU domain factors 74 65 (+) 0.913 ctgggATTAcaggggtggg
Insulinoma associated factors 74 68 (+) 0.909 ttacaGGGGtggg
Krueppel like transcription factors 78 70 (+) 0.955 ttacagGGGTgggccac
C2H2 zinc finger transcription factors 2 84 73 (-) 0.889 ggcgcggtggcCCACccctgtaa
GLI zinc finger family 77 70 (-) 0.892 tggcCCACccctgta
ZF5 POZ domain zinc finger 90 83 (+) 0.879 cacCGCGcccggcct
RNA polymerase II transcription factor II B 84 81 (+) 1 ccgCGCC
Homolog to deformed epidermal autoregulatory factor-1 from D. melanogaster99 90 (+) 0.746 cgcCCGGcctttttcttaa
AT-binding transcription factor 104 96 (+) 0.795 cctttttcttAATTttt
Ccaat/Enhancer Binding Protein 103 96 (-) 0.948 aaaattaaGAAAaag
Homeodomain transcription factors 108 99 (+) 0.866 tttttcTTAAtttttaaaa
snRNA-activating protein complex 108 99 (+) 0.733 tttttCTTAatttttaaaa
NK6 homeobox transcription factors 106 99 (+) 0.917 tttcTTAAtttttaa
Paralog hox genes 1-8 from the four hox clusters A, B, C, D 110 101 (+) 0.813 tttcttAATTtttaaaaat
NKX homeodomain factors 110 101 (+) 0.957 tttctTAATttttaaaaat
Hepatic Nuclear Factor 1 110 102 (+) 0.848 tCTTAatttttaaaaat
AT-binding transcription factor 111 103 (-) 0.844 tatttttaaaAATTaag
AT rich interactive domain factor 117 107 (-) 0.961 ctttaATATttttaaaaatta
Hepatic Nuclear Factor 1 117 109 (-) 0.806 cTTTAatatttttaaaa
Special AT-rich sequence binding protein 116 109 (-) 0.968 tttAATAtttttaaa
AT rich interactive domain factor 124 114 (+) 0.95 taaaaATATtaaagttttatc
NK6 homeobox transcription factors 119 112 (-) 0.852 aactTTAAtattttt
Vertebrate TATA binding protein factor 123 115 (+) 0.82 aaatattAAAGttttat
Homeodomain transcription factors 125 116 (-) 0.975 ggataaaacttTAATattt
MYT1 C2HC zinc finger protein 124 118 (+) 0.99 ttaAAGTtttatc
Vertebrate caudal related homeodomain protein 130 121 (+) 0.908 ttaaagtTTTAtcccattc
GATA binding factors 128 122 (-) 0.931 atggGATAaaact
C2H2 zinc finger transcription factors 5 131 124 (-) 0.883 ggaatgGGATaaaac
Paralog hox genes 1-8 from the four hox clusters A, B, C, D 136 127 (-) 0.959 caacaggAATGggataaaa
Human and murine ETS1 factors 139 129 (-) 0.856 gttcaacAGGAatgggataaa
TEA/ATTS DNA binding domain factors 135 129 (+) 0.944 tccCATTcctgtt
Human and murine ETS1 factors 155 145 (-) 0.889 ttaaatcaGGAAtatggttca
Growth factor independence transcriptional repressor 155 148 (-) 0.864 ttaAATCaggaatat
Vertebrate TATA binding protein factor 159 151 (-) 0.855 actttTAAAtcaggaat
HOX - PBX complexes 160 152 (+) 0.947 ttcctGATTtaaaagtt
Brn POU domain factors 165 156 (+) 0.881 ctGATTtaaaagttggaaa
MYT1 C2HC zinc finger protein 165 159 (+) 0.887 taaAAGTtggaaa
Hypoxia inducible factor, bHLH/PAS protein family 174 166 (+) 0.897 gttggaaaCGTGgtgaa
Nuclear factor of activated T-cells 176 167 (+) 0.875 gttGGAAacgtggtgaacc
NKX homeodomain factors 192 183 (+) 0.844 acctagAAGTatttgttgc
SWI/SNF related nucleophosphoproteins with a RING finger DNA binding motif187 182 (-) 0.987 aaatACTTcta
X-box binding factors 203 194 (-) 0.876 agacaaacccagCAACaaa
Interferon regulatory factors 209 199 (-) 0.694 acctGAAGacaaacccagcaa
Glucocorticoid responsive and related elements 214 205 (+) 0.896 gtttgtcttcagGTTCtgt
MEF3 binding sites 213 207 (+) 0.922 tctTCAGgttctg
X-box binding factors 228 219 (-) 0.867 tagaaaaccgagCAACaga
PAX-2/5/8 binding sites 239 225 (+) 0.805 ctgttGCTCggttttctagttccccacct
Interferon regulatory factors 236 226 (-) 0.866 tgggGAACtagaaaaccgagc
Human and murine ETS1 factors 241 231 (-) 0.978 ctaggtggGGAActagaaaac
C2H2 zinc finger transcription factors 2 243 232 (+) 1 gttttctagttCCCCacctagtc
Myeloid zinc finger 1 factors 237 232 (-) 1 gtGGGGaacta
Serum response element binding factor 250 241 (-) 0.87 taaccCAGActaggtgggg
X-box binding factors 254 245 (+) 0.89 acctagtctggGTTActct
Vertebrate SMAD family of transcription factors 248 243 (+) 0.997 ctaGTCTgggt
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Table 2.1. Genomatix predictions in the NANOG proximal promoter: continued
Predicted protein Start End Strand P
X-box binding factors 262 253 (-) 0.912 gtagctgcagaGTAAccca
Octamer binding protein 273 266 (-) 0.958 gtaATGCaaaagtag
Motif composed of binding sites for pluripotency or stem cell factors278 269 (+) 0.998 tacttttGCATtacaatgg
PAR/bZIP family 277 269 (-) 0.916 cattgTAATgcaaaagt
Octamer binding protein 276 269 (+) 0.816 cttttGCATtacaat
RXR heterodimer binding sites 286 274 (-) 0.794 caccaaGGCCattgtaatgcaaaag
Activator/repressor binding to transcription initiation site 283 273 (-) 0.882 caaggCCATtgtaatgcaaaa
Brn POU domain factors 282 273 (+) 0.944 tttgcATTAcaatggcctt
Estrogen response elements 286 275 (-) 0.884 caccAAGGccattgtaatgcaaa
SOX/SRY-sex/testis determinig and related HMG box factors 291 279 (+) 0.946 gcattACAAtggccttggtgagact
Vertebrate steroidogenic factor 287 280 (-) 0.993 tcacCAAGgccattg
SOX/SRY-sex/testis determinig and related HMG box factors 315 303 (-) 0.883 aattctcagttAATCccgtctacca
Bicoid-like homeodomain transcription factors 310 302 (-) 0.985 tcagtTAATcccgtcta
Hepatic Nuclear Factor 1 315 307 (-) 0.908 aattctcaGTTAatccc
Cellular and viral myb-like transcriptional regulators 315 308 (+) 0.898 gattAACTgagaatt
Core promoter initiator elements 312 307 (-) 0.944 tcTCAGttaat
FAST-1 SMAD interacting proteins 324 316 (-) 0.871 accctTGTGaattctca
CP2-erythrocyte Factor related to drosophila Elf1 333 324 (-) 0.854 tACTGacccacccttgtga
v-ERB and RAR-related orphan receptor alpha 339 328 (+) 0.757 acaagggtggGTCAgtagggggt
MAF and AP1 related factors 338 328 (+) 0.918 caagggTGGGtcagtaggggg
Testis-specific bHLH-Zip transcription factors 331 326 (+) 0.944 gGGTGggtcag
C2H2 zinc finger transcription factors 2 348 337 (-) 0.92 ggcgggcacaCCCCctactgacc
Chorion-specific transcription factors with a GCM DNA binding domain342 335 (-) 0.863 cacacCCCCtactga
GLI zinc finger family 342 335 (-) 0.864 cacaCCCCctactga
Krueppel like transcription factors 344 336 (+) 0.967 tcagtaGGGGgtgtgcc
C2H2 zinc finger transcription factors 2 351 340 (-) 0.934 cctggcgggcacaCCCCctactg
Krueppel like transcription factors 346 338 (+) 0.97 agtaggGGGTgtgcccg
GC-Box factors SP1/GC 347 339 (+) 0.934 gtagGGGGtgtgcccgc
Pleomorphic adenoma gene 354 343 (+) 1 taGGGGgtgtgcccgccaggagg
Vertebrate homologues of enhancer of split complex 347 340 (+) 0.929 agggggtGTGCccgc
Retinoblastoma-binding proteins with demethylase activity 343 339 (-) 0.965 GCACacccc
CTCF and BORIS gene family, transcriptional regulators with 11 highly conserved zinc finger domains365 352 (+) 0.824 tgtgcccgccaggaGGGGtgggtctaa
Selenocysteine tRNA activating factor 364 353 (-) 0.795 tagaCCCAcccctcctggcgggc
Krueppel like transcription factors 360 352 (+) 0.901 ccgccaggagGGGTggg
Krueppel like transcription factors 364 356 (+) 0.954 caggagGGGTgggtcta
C2H2 zinc finger transcription factors 2 370 359 (-) 0.912 tcaccttagacCCACccctcctg
GC-Box factors SP1/GC 365 357 (+) 0.898 aggaggGGTGggtctaa
RXR heterodimer binding sites 374 362 (+) 0.846 ggaggggtgggtctaAGGTgataga
Peroxisome proliferator-activated receptor 373 362 (+) 0.795 gaggggtgggtctaAGGTgatag
Nuclear receptor subfamily 2 factors 376 364 (+) 0.813 aggggtgggtctaAGGTgatagagc
Brn-5 POU domain factors 385 374 (-) 0.818 aTAATgaaggctctatcacctta
C2H2 zinc finger transcription factors 4 378 372 (-) 0.98 agGCTCtatcacc
Paralog hox genes 1-8 from the four hox clusters A, B, C, D 389 380 (-) 0.822 atttaTAATgaaggctcta
Brn POU domain factors 393 384 (-) 0.906 ctagaTTTAtaatgaaggc
Brn POU domain factors 396 387 (+) 0.919 ttCATTataaatctagaga
Plant TATA binding protein factor 393 386 (+) 0.909 tcatTATAaatctag
HOX - PBX complexes 395 387 (-) 0.949 ctctagaTTTAtaatga
Vertebrate TATA binding protein factor 396 388 (+) 0.923 cattaTAAAtctagaga
C2H2 zinc finger transcription factors 10 401 394 (+) 0.852 aatCTAGagactcca
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To rapidly identify key regulators, we initially constructed a series of deletions 
(del1-5) (Table 2.2, Fig. 2.4A) within the promoter sequence to scan for regions 
essential for NANOG promoter activity in a luciferase reporter assay.  The 
transcriptional start site was left intact in all constructs so that transcription was 
not artificially disrupted by the deletions.  In pluripotent NCCIT cells, loss of distal 
promoter elements had little to no effect on NANOG promoter activity.  In 
contrast, the del4 construct that deleted the OCT4/SOX2 consensus sequences 
displays an ~2-fold reduction in transcriptional activity, consistent with previous 
reports in ESCs indicating this motif is essential for high levels of promoter 
activation in pluripotent cells.  Surprisingly, the del5 construct exhibited ~10-fold 
lower activity relative to WT, suggesting that there are regulatory elements in the 
del5 region with an even greater regulatory effect on NANOG expression than 
OCT4/SOX2. 
	     41 
 
Based on these observations in pluripotent NCCIT cells, we then screened the 
deletion constructs in a small panel of NANOG+ cancer cell lines (Fig. 2.4C).  
Intriguingly, different cell lines and cancer types display varying promoter 
element-requirements.  For example, NCCIT cells required the del4 element for 
activity while more differentiated MCF7, MDA-MB-231, and LNCap cells that do 
not express high levels of OCT4 are not affected by del4 (Fig. 2.4C).  
Furthermore, del1 had little to no inhibitor effect on promoter activity in NCCIT 
and HER2– MCF7 breast cancer cells, yet greatly increased activity in MDA-MB-
231 breast and LNCap prostate cancer cells, suggesting that this region may be 
bound by a differentially expressed repressor of NANOG (Fig. 2.4C).  
Identification of these repressors could provide valuable details about how 
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NANOG is regulated in different cancer cell types.  However, the present 
research is focused on activator identification, so we chose to pursue regions 
required for full activity. 
 
2.5.2. Two GC-rich KLF motifs are broadly required for NANOG expression 
In contrast to differentially required regions, the del5 construct displayed greatly 
reduced transcriptional activity in all cell types tested.  The del5 region does not 
contain traditional TATA or CAAT box motifs associated with general 
transcriptional machinery, suggesting that the decrease in promoter activity may 
not be due to nonspecific transcriptional inhibition.  MatInspector predicted 2 GC-
rich motifs to be bound by Kruppel-like factor (KLFs) (Fig. 2.5A).  To test if these 
motifs are essential for promoter activity, dinucleotide substitutions were 
introduced to disrupt KLF recognition (39) (Fig. 2.5A).  The OCT4 binding site 
was mutated as well to serve as an additional control (40).  In NCCIT cells, 
mutation of the 5’ motif (mutKLF’) or the 3’ motif (mutKLF’’) caused a 50% and 
90% reduction in promoter activity, respectively.  In contrast, mutation of the 
OCT4 site only perturbed promoter activity in NCCIT cells and had no impact on 
activity in more differentiated MCF7 cells.  These results indicate that the KLF 
motifs are essential for NANOG promoter activity independent of cellular 
differentiation status and therefore KLF activators may be a common and pivotal 
regulator of NANOG expression in human cancer cells. 
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2.5.3. Loss of KLF4 downregulates NANOG expression in cancer cells 
KLF4 in particular has been documented to be a strong activator of the NANOG 
promoter in ESCs (39).  We therefore chose to focus examine whether KLF4 was 
required for NANOG expression in cancer cells.  Short-hairpin RNAs were 
designed to target KLF4, NANOG, and a scrambled sequence as a negative 
control.  Transfecting NCCIT cells with these shRNAs indicated that robust 
downregulation could be achieved with the targeted constructs (Fig. 2.6A).  Both 
shKLF4 and shNANOG reduced mRNA levels of their target genes by ~90%, 
while OCT4 mRNA levels were not reduced (Fig. 2.6A).  Strikingly, KLF4-
knockdown strongly reduced NANOG mRNA levels, suggesting that KLF4 may 
be important for full NANOG expression (Fig. 2.6A).  
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OCT4 may be unperturbed by KLF4 and NANOG knockdown due to an 
independent regulatory mechanism in NCCIT cancer cells than in ESCs, or, more 
likely, because residual KLF4 and NANOG protein may persist in the cells 
following knockdown.  When NANOG-depleted NCCIT cells were followed for 4+ 
days after transfection, OCT4 levels decreased indicating that there is a delay in 
the responsiveness of OCT4 expression to KLF4 and NANOG knockdown (Fig. 
2.6B). 
 
To further confirm that KLF4 is a direct regulator of NANOG, we performed 
additional ChIP assays to determine KLF4 localization within the genome.  We 
observed that KLF4 was enriched at the NANOG1 locus in NCCIT cells,  
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indicting that KLF4 is a direct and essential positive regulator of NANOG 
expression (Fig. 2.7). 
 
2.6.  Conclusions and Future Directions 
The data presented here indicate the coactivator p300 is a direct and positive 
regulator of the NANOG1 gene in pluripotent human cancer cells.  To our 
knowledge, this is the first work to characterize an essential coactivator for ESC-
associated genes in a non-ESC context.  This information can be used to design 
strategies to modulate ESC gene expression profiles as well as guide rational 
anticancer drug development.  Furthermore, these findings reveal significant 
similarities between p300/NANOG function in ESCs and cancer cells. p300 
appears to control NANOG expression and function, regardless of cell 
differentiation status, indicating that at least some of the regulatory mechanisms 
in place in ESCs retain or regain activity in pathological cell states. 
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The finding that p300 directly regulates the NANOG1 locus in pluripotent NCCIT 
cells stands in contrast to findings from other groups that the NANOGP8 locus is 
a major source of NANOG expression in cancer cells (15, 35).  These differences 
could partially be attributable to the various cell lines and cancer types examined 
(embryonal carcinoma and HNSCC here vs. prostate and colon), as well as 
differences in techniques.  Those studies concluded NANOGP8 was expressed 
based on sequencing and AlwNI digests of cDNA libraries.  However, given the 
high degree of sequence identity between NANOG1 and NANOGP8, and the 
relatively error-prone nature of RNA polymerase, the sequencing results may be 
unreliable.  In support of this, Jeter et al. (15) reported multiple independent 
mutations within sequenced NANOG cDNAs, indicating a high rate of nucleotide 
substitution either in their cultures or in their readout. 
 
We argue that by examining the promoter occupancy of activator and 
coactivators, we can more concretely identify the active gene loci.  Here, we 
found that both p300 and H3Kac were significantly enriched at the NANOG1 
proximal promoter, whereas little to no detectable levels were found at the 
analogous NANOGP8 region (Fig. 2.3B).  Protein localization more strongly 
indicates function and transcriptional activity, and therefore we conclude that 
NANOG1 is the predominant source of NANOG in the cell lines studied here. 
 
The work presented here also represents the first analysis of NANOG promoter 
requirements in cancer cells.  By systematically deleting and mutating proximal 
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promoter elements, we have identified both differentially required transcription 
binding sites, as well as a pair of critical KLF consensus motifs (Fig. 2.4-5).  
Disruption of either KLF’ or KLF’’ strongly inhibits NANOG promoter activity (Fig. 
2.5) independent of cancer cell type or differentiation status, suggesting that KLF 
factors may be a common requirement for NANOG expression in cancer.  In 
support of this, knockdown of KLF4 dramatically reduced NANOG mRNA 
expression in NCCIT cells (Fig. 2.6), confirming that KLF4 is involved in NANOG 
regulation. 
 
KLF4 is a known activator of NANOG in ESCs, but had not previously been 
considered to be a driver of cancer self-renewal.  Interestingly, KLF4 has been 
reported to have both oncogenic and tumor suppressor functions (41).  KLF4 is 
frequently overexpressed in squamous cell carcinomas and breast cancers, and 
gain of KLF4 appears to represent an early event in tumor development (42, 43).  
Furthermore, KLF4 also possesses reprogramming capacity and is often 
including in inducible pluripotent stem cell generation to increase dedifferentiation 
efficiency (44), suggesting that gain of KLF4 in cancer or precancerous cells 
could activate NANOG expression and thereby establish a self-reinforcing, stem 
cell-like genetic program that confers both growth and survival advantages. 
 
Intriguingly, the KLF4 activator has also been reported to rely on p300 for full 
transcriptional activation (45-48).  The cooccupancy of both KLF4 and p300 at 
the NANOG1 promoter raises the possibility of a physical connection between 
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KLF4 and p300 that could account for the mutual requirements for both activator 
and coactivator.  Several reports have found that KLF4 is able to associate with 
p300 (47, 48), suggesting a potential route by which p300 could be recruited to 
the DNA.  Identifying the potential activator-coactivator interactions that lead to 
p300 recruitment to the NANOG1 promoter could reveal further details into the 
regulatory complexes and mechanisms leading to NANOG expression, as well as 
isolate protein-protein interactions to target in small molecule probe 
development.  Such tools could provide new and exciting opportunities for 
modulating NANOG expression in cancer. 
 
2.7. Acknowledgements 
I would like to acknowledge the contributions of our collaborators Prof. Quintin 
Pan (Ohio State University) , Dr. Xiujie Xie, and Dr. Manchao Zang for their work 
generating the p300-knockdown HNSCC cell lines all data associated with their 
phenotypes.  
 
2.8.  Materials and methods 
Cell lines 
NCCIT, MCF7, MDA-MB-231, and LNCap cells were purchased from ATCC.  
UMSCC74B cells were a gift from Dr. Thomas Carey (University of Michigan).  
NCCIT cells were grown in RPMI media 1640 (Life Technologies, 11875) 
supplemented with 10% fetal bovine serum (Atlanta Biologicals, S11195) in a 37 
ºC incubator with 5% CO2.  All other cell lines were cultured in Dulbecco’s 
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Modified Eagle Medium (DMEM) (Invitrogen, 11965) supplemented with 10% 
fetal bovine serum. 
 
Chromatin immunoprecipitation assays 
ChIP assays were performed on >90% confluent cells in 10-cm plates using the 
Abcam ChIP (ab-500) protocol..  Briefly, cells were dissociated by trypsin digest 
and resuspended in media + 10% FBS before counting.  10 x 106 cells were then 
pelleted by centrifugation and then washed with chilled PBS.  Cells were then 
fixed with 1% formaldehyde for 10 min at room temperature before quenching 
with 1.25 M glycine.  The fixed cells were washed with chilled PBS and 
resuspended in lysis buffer.  Samples were then pelleted to collect the fixed 
chromatin.  Mild sonication was carried out to yield sheared chromatin averaging 
~500 bp in size.  Immunoprecipitations were conducted on the sheared 
chromatin using anti-histone H3 (Abcam, ab1791), anti-p300 (Santa Cruz, sc-584 
X), anti-acetylated histone H3 antibody (Millipore, 06-599), or Protein A beads 
alone as a negative control.  The recovered DNA was used as a template for 
qPCR reactions using SYBR Green (Applied Biosystems, 4309155) according to 
the manufacturer’s instructions. 
 
Plasmids and cloning 
The NANOG promoter-driven luciferase plasmid was originally purchased from 
Addgene (pNANOG-Luc, plasmid 25900).  Deletions and point mutations were 
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then introduced using site-directed mutagenesis.  Mutants were validated by 
DNA sequencing. 
 
Transfections 
NCCIT cells were transfected using OptiMEM media (Invitrogen) and 
Lipofectamine LTX (Invitrogen) according to an optimized protocol.  Briefly, 
DNA•liposome complexes were formed in OptiMEM by sequentially adding DNA, 
PLUS reagent, and LTX and incubating for 30 min at room temperature.  Four 
volumes of RPMI (10% FBS) was then added to the transfection mix before 
applying to the cells.  The cells were incubated with the transfection mix for 24 h 
before switching media and grown for an addition 24 h. 
 
Luciferase assays 
10,000 cells were plated in 96-well format with 100 µl media + 10% FBS.  After 
overnight incubation, the media was replaced with transfection mix: 100 µL 
media with 5 ng/ml Renilla luciferase plasmid (pRLSV40) and 395 ng/ml firefly 
luciferase plasmid.  After 48 h incubation, luciferase activity is measured on a 
Berthold luminometer with firefly substrate from the Dual-Luciferase Assay 
Reporter System (Promega, E1980). 
 
Knockdowns 
100,000 NCCIT cells were cotransfected with a puromycin-selectable plasmid 
(250 ng/ml) and either scrambled or targeted shRNA vectors (1 µg/ml).  Cells 
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were allowed to grow 24 h before selecting for transfected cells with 2 µg/ml 
puromycin in standard growth media.  Cells were incubated for 72 h before 
harvesting RNA or protein for analysis, and fresh media with puromycin was 
applied every 24 h. 
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Chapter 3 
Identification of key p300 functions during NANOG transcription 
 
3.1. Abstract 
Coactivator-mediated transcription involves a variety of protein-protein 
interactions (PPIs) and enzymatic activities to regulate gene expression.  
Multifunctional coactivators such as p300 can fulfill differential roles depending 
upon the target gene context, and as a result it is often unclear whether a 
coactivator acts as a scaffolding protein, a catalytic subunit, or a combination of 
the two.  Based on our finding that p300 is an essential and direct regulator of 
NANOG expression in cancer cells, we sought to dissect the relevant PPI and 
enzymatic contributions of p300 to NANOG transcription.  Individual domains 
within p300 were systematically perturbed through the use of dominant-negative 
constructs, site-directed mutagenesis, and small molecule inhibitors in order to 
identify the crucial domains participating in NANOG transcription.  We found that 
the CH1 domain in particular appears to be essential for overall p300 activity, 
suggesting a role in initial recruitment of p300 to the NANOG promoter.  
Additionally, we found that inhibition of the histone acetyltransferase (HAT) 
domain rapidly depletes p300-mediated histone acetylation at the NANOG 
promoter and downregulates NANOG expression in pluripotent cancer cells.  
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Interestingly p300 HAT inhibition does not disrupt p300 localization, suggesting 
that HAT activity is not necessary for p300 occupancy at the NANOG promoter.  
These results allowed us to propose a model for p300-mediated NANOG 
activation that reveals new potential targets for modulating NANOG expression. 
 
3.2. p300 domains and their interactions 
Eukaryotic gene activation requires the concerted function of transcription factors 
and coactivators (1).  Transcriptional activators bind cognate sites in the 
promoters and enhancers of target genes and stimulate transcription by bringing 
the basal transcriptional machinery, including general factors and RNA Pol II 
itself, to the transcriptional start site (2, 3).  Although some activators directly 
interact with the general factors such as TFIID, in most cases, additional proteins 
or multiprotein complexes termed coactivators are required to facilitate this 
process (4-6).  Initially, coactivators were viewed as adaptor protein that connect 
the sequence-specific transcription factors to the basal transcription machinery, 
yet it was later discovered that some coactivators have additional functions.  In 
eukaryotic cells, DNA wraps around histone octamers to assemble nucleosomes, 
which are further packaged into condensed chromatin that is inaccessible for 
transcription (7).  Several classes of transcriptional coactivators were found to 
possess chromatin-remodeling or modification activity, which opens the 
chromatin structure to allow effective gene transcription (6). 
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The coactivator p300 performs both of these functions: bridging of DNA-binding 
and general transcription factors, and relaxation of chromatin through its intrinsic 
histone acetyltransferase (HAT) activity (Fig. 3.1A)(8-10).  p300 is a large,  
 
multifunctional protein with a catalytic HAT domain as well as activator-binding 
domains that include the Cysteine-Histidine-rich region 1 (CH1)(11, 12), the 
CREB- and MLL-interacting KIX domain (13), another Cystein-Histidine-rich 
region (CH3)(12, 14), and the interferon-binding domain (IBiD)(Fig. 4.1A)(15, 16).  
These domains mediate the protein-protein interactions with DNA-binding 
transcription factors and the basal transcription machinery, as well as other 
coactivators such as PCAF/GCN5 (17).  The activator-binding domain 
interactions are frequently with partners that are intrinsically disordered in 
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isolation and undergo binding-coupled folding.  Several structures of p300 
domains in complex with transcriptional activation domains (TADs) have been 
described and shed light on the diverse mechanisms of coactivator recruitment 
during transcriptional activation (Fig. 3.1B). 
 
The most extensively studied interaction is that between the so-called kinase-
inducible domain (pKID) of CREB and the KIX domain of p300 (18).  The 
pKID•KIX complex has been determined by solution nuclear magnetic resonance 
(NMR) spectroscopy (19).  The KIX domain is composed of a three-helix bundle 
with two additional short 310 helices and is relatively stable on its own compared 
to the disordered pKID in isolation.  pKID binds a largely hydrophobic groove 
formed by helices H1 and H3 of KIX, with a Kd of ~700 nM.  This is ~100-fold 
tighter than the interaction between unphosphorylated KID peptide and KIX.  The 
NMR structure suggested that the increased binding affinity in pKID stems from 
an interaction between the phosphate group and Y658 of KIX (19, 20). 
 
The binding mode of pKID to KIX, however, is not representative of all TAD•KIX 
interactions.  For instance, the TAD of the transcription factor c-MYB binds the 
same site as pKID (KIX H3-H4), but binds as a single helix (21).  Furthermore, a 
second binding site for TADs was identified on the opposite face of KIX involving 
a hydrophobic groove formed by the H2 and H3 helices.  This second site can be 
occupied by the TAD of the myeloid-lymphoid leukemia (MLL) protein.  
Remarkably, both c-MYB and MLL TADs can bind to the two KIX sites 
	     60 
simultaneously and cooperatively (22-24).  This potential allostery between 
activator-binding sites in KIX could account for the concerted recruitment of p300 
by CREB and the viral protein Tax (25).  A variety of other TADs have been 
reported to bind to one or both sites on KIX, including c-JUN, FOXO3a, and p53 
(26-28).  The binding of these TADs vary greatly, with differences in binding 
mode, affinity, and promiscuity– all common features of activator-coactivator 
PPIs. 
 
Another well-documented activator-binding domain of p300 is the CH1 domain, 
and the highly similar CH3 domain.  CH1 and CH3 are each comprised of four 
amphiphatic helices that fold around three HCCC-type zinc-binding sites (12, 29, 
30).  The structures of CH1 and CH3 are similar, however the fourth helix is 
found in opposite orientations in the two domains and has been invoked as a 
possible determinant of binding specificity for different TADs (29). 
 
The TADs of some activators are specific for CH1 or CH3, whereas others 
interact with both as well as other p300 activator-binding domains.  For example, 
the highly promiscuous TAD of p53 binds to both CH1 and CH3 (31, 32), as well 
as both KIX sites and the IBiD domain (31).  In contrast, the CH1 domain 
recognizes the C-terminal activation domain of HIF1α, which functions in the 
maintenance of cellular oxygen homeostasis by inducing transcription of adaptive 
genes under hypoxic conditions (33).  The HIF1α TAD, which is intrinsically 
disordered in isolation, wraps around the CH1 domain and folds into three short 
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helices linked by extended loop regions.  This creates a large surface area for 
interaction resulting in a tight HIF1α•CH1 interaction (Kd ~ 7 nM) (34).  The 
CBP/p300-interacting transactivator 2 (CITED2) protein negatively regulates 
HIF1α activity by competing for p300 binding (24, 35-37).  CITED2 wraps around 
CH1 similarly to HIF1α, with a partially overlapping binding site and comparable 
affinity (Kd ~ 13 nM) (38). 
 
These studies show that p300 can participate in a variety of protein-protein 
interactions, with diversity observed even within the same domain.  Thus, in the 
absence of known interactions (such as at the NANOG promoter), it is difficult to 
predict which domain(s) may be essential for coactivator function.  We therefore 
set out to identify crucial p300 domains for NANOG expression by systematically 
testing the gain and loss of function for each in order to guide future experiments 
and potential modulation strategies. 
 
3.3 Identification of essential activator-binding domains 
Given the diverse and potentially multivalent types of interactions the p300 
activator-binding domains are capable of engaging in, we sought to first identify 
which domain(s) are required for full p300 activity at the NANOG promoter.  To 
do this, we cloned out individual domains from the human p300 sequence for 
“squelching” experiments (Fig. 3.2A,B).  p300 and the related coactivator CBP 
are expressed at limiting concentrations in the nucleus, and thus transcription of 
many p300/CBP-target genes is dose-dependent (39-41).  Therefore, 
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overexpressed domains can compete with endogenous full-length p300 for 
binding to DNA-bound activators and thereby act as dominant-negative 
constructs to inhibit p300-dependent transcription. 
 
 
Immunoblotting confirmed robust expression of the p300/CH1, p300/KIX, and 
p300/CH3 constructs (Fig. 3.2C).  Furthermore, p300/CH1 or p300/KIX 
overexpression was generally tolerated by the cells, with p300/CH1 eliciting an 
~15% decrease in cell viability and KIX having no significant impact on viability 
(Fig. 3.2D).   
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To confirm that the expressed domains are functional we tested their ability to 
suppress the transcriptional activity of two Gal4-fused transcriptional activation 
domains (TAD): the KIX-dependent TAD MLL and the CH1-dependent TAD 
HIF1α.  As expected, increasing amounts of KIX dose-dependently reduced the 
activity of Gal4-MLL, but had no effect on Gal4-HIF1α (Fig. 3.3A).  In contrast, 
CH1 dose-dependently inhibited HIF1α-driven transcription without affecting MLL 
activity.  These results confirm that the CH1 and KIX constructs can inhibit 
transcription from model p300-dependent TADs.   
 
When stably overexpressed in the head and neck squamous cell carcinoma 
(HNSCC) cell line UMSCC74A, the CH1 domain inhibited NANOG transcriptional 
activity by >50% (Fig. 3.4A,B).  Furthermore, p300/CH1 decreased the 
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transcriptional activity of a NANOG-driven reporter gene (Fig. 3.2B), as well as 
reduced the ability of UMSCC74A cells to form tumorspheres by 80% (Fig 3.4C), 
suggesting a strong decrease in CIC frequency.  To test this, 
immunocompromised mouse xenograft studies were performed to evaluate the in 
vivo potential of UMSCC74A CICs to generate new tumors.  As anticipated, 
control UMSCC74A cells robustly formed palpable tumors within 60 days (Fig. 
3.4D).  Remarkably, CH1-overexpressing cells were unable to found tumors even 
when 1 x 106 cells were injected, indicating that the dominant negative form of 
CH1 effectively blocks CIC potential in vivo. 
 
When these studies were extended to pluripotent NCCIT cells, neither CH1 nor 
KIX overexpression were able to inhibit transcription from the NANOG proximal 
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promoter, either alone or in combination (Fig. 3.3B).  Furthermore, p300 domain 
overexpression also failed to inhibit endogenous expression levels of NANOG 
(Fig. 3.3C), which would suggest that the CH1 and KIX domains are not essential 
p300 domains for NANOG activation.  However, further positive controls testing 
the ability of the dominant-negative domains to inhibit endogenous gene 
expression also failed.  p300/CH1 overexpression failed to inhibit DFO-induced 
VEGFA expression in HeLa cells (Fig. 3.3D), whereas p300/KIX overexpression 
had no significant effect on MLL-driven HOXA9 expression (Fig. 3.3E), indicating 
that the independent domain constructs are not suitable for perturbing expression 
of endogenous genes in NCCIT cells. 
 
We therefore designed an alternative method for systematically assessing the 
structural domains of p300 required for NANOG expression.  We reasoned that, 
due to the independent folding and function of the activator-binding domains 
within p300, we could create in-frame deletions within the coactivator for internal 
loss-of-function studies (Fig. 3.5A).  Other groups have used his technique to 
study the roles of p300 in hematopoiesis (42).  A series of internal domain 
deletions within p300 were constructed (Fig. 3.5A), and their expression was 
confirmed by immunoblotting (Fig. 3.5B).  Due to the high molecular weight of 
full-length p300, small differences in molecular weight were difficult to resolve by 
standard SDS-PAGE. 
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To confirm that the deleted domains had functional effects, the mutant 
coactivators were tested for their ability to enhance HIF1α- and MLL-driven 
reporter gene epxression (Fig. 3.5C).  Wild-type (WT) p300 was able to strongly 
enhance GAL4-HIF1a activity.  As anticipated, this enhancement was completely 
lost when the CH1 domain was deleted (∆CH1)(Fig. 3.5C).  Loss of other 
domains had little to no inhibitory effect on coactivator-mediated enhancement, 
except for ∆CH3 which is structurally very similar to the CH1 domain and has 
been shown to affect HIF1a-mediated transcription (43).  In contrast, ∆CH1 had 
no impact on GAL4-MLL activity (Fig. 3.5D), while ∆KIX showed ~3-fold lower 
activity relative to WT, indicating that the internal domain deletions selectively 
perturb coactivator functions.  Interestingly, ∆CH3 also displayed a mild (~20%) 
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reduction in MLL activity enhancement.  KIX and CH3 are not structurally similar 
(Fig. 3.1B), and so far there are no reports of a KIX-CH3 or MLL-CH3 interaction 
that could potentially account for this observation.  The possibility of intraprotein 
interactions within p300 is intriguing but currently outside the scope of the work 
presented here. 
 
We next tested the ability of ∆CH1 and ∆KIX to enhance NANOG-promoter 
activity in a luciferase reporter assay.  WT p300 increased promoter activity ~4-
fold over an empty vector control (Fig. 3.6A), consistent with the proposal that 
p300 is a limiting coactivator of NANOG expression.  Strikingly, the ability of 
∆CH1 to enhance NANOG promoter activity was strongly attenuated (Fig 3.6A), 
suggesting that the CH1 domain may be a key mediator of p300 function.  In 
contrast, ∆KIX had no effect on promoter activity, indicating that the KIX domain 
may be largely dispensable (Fig. 3.5A).  The loss of other domains such as  
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deletions of ∆CH1/∆KIX and ∆CH1/∆CH3 did not exhibit any greater defects than 
∆CH1 alone (Fig. 3.6B), suggesting: i) that the CH1 domain is the major PPI 
interface for p300 during NANOG transcription, and ii) that the other domains do 
not cooperate with CH1 such as in the formation of multivalent interactions.  The 
CH1 domain therefore appears to be of crucial importance for p300 function 
here. 
 
The CH1 domain itself adopts a compact globular fold around three zinc-binding 
sites (Fig. 3.7A) (12, 29) and this folded structure serves as a template for 
intrinsically disordered activators to bind (29).  Mutation of the key zinc-
coordinating residues to alanine disrupts activator-CH1 interactions and impairs 
CH1-mediated transcription (44).  Some residues appear to be essential for 
general CH1-domain interactions, while others have effects on specific  
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interactions.  For example, C379A in CBP CH1 abrogates binding to HIF1a, NF-
κB, and Mrg1, whereas H407A can still bind HIF1a and NF-kB but not Mrg1 (44).  
Therefore, it appears that the zinc bundles are directly involved in interactions 
made by some but not all proteins that bind the CH1 domain.  We reasoned that, 
in the absence of a known binding partner at the NANOG promoter, we could 
further explore the role of the CH1 domain by introducing single amino acid 
substitutions at the zinc-coordinating residues.  Three cysteine residues (C364, 
C388, and C406), representing each of the three zinc-binding sites, were 
mutated within full-length p300 and tested for their ability to enhance NANOG 
promoter activity as described above. 
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As shown in Fig. 3.7B, p300 WT consistently enhanced promoter activity 4-5-
fold, while ∆CH1 was statistically indistinguishable from basal promoter activity.  
Interestingly, all three point mutations (C364A, C388A, and C406A) exhibited 
reduced enhancement potential relative to WT.  C364A was not found to be 
different from ∆CH1 (ANOVA), while C388A and C406A showed milder 
impairments in activity (~3-fold enhancement).  These results further 
demonstrate that disruption of the CH1 domain, either by deletion or point 
mutation, greatly reduces the ability of p300 to function as a transcriptional 
coactivator at the NANOG promoter.  Furthermore, the fact that all three zinc-
binding sites are essential for CH1 function suggests that complete integrity of 
the CH1 domain is required for full activity.  Local misfolding due to improperly 
coordinated metal ions is sufficient to disrupt CH1 function, likely by disrupting 
the key interaction(s) CH1 engages in. 
 
Taken together, these data reveal the CH1 domain to be a core contributor to 
p300 function at the NANOG promoter. 
 
3.4. Investigating the role of p300 HAT activity 
In addition to the role of the CH1 domain, we also wished to explore the potential 
catalytic contributions of p300 in NANOG expression.  p300 contains a HAT 
domain that acetylates nucleosomal histones (Fig. 3.1A)(8, 9).  In vitro, p300 
acetylates all acetylation sites on histones H2A and H2B, and preferentially 
acetylates histone H3 at K14 and K18, and histone H4 at K5 and K8 (45).  In 
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addition to the histone N-terminal tails, p300 is also able to acetylate a number of 
non-histone proteins including transcriptional activators (46-49). The requirement 
for p300 HAT activity can be gene-dependent (50), so it is possible that the HAT 
domain may be dispensable for NANOG expression.  We therefore sought to 
establish the role of p300 enzymatic activity at the NANOG promoter. 
 
A number of HAT inhibitors have been reported for p300 (51-56), but all suffer as 
chemical probes due to issues with toxicity, solubility, cell permeability, and 
selectivity.  Bowers et al. (57) identified the pyrazolone compound C646 (Fig. 
3.8A) as a potent and novel lysine-CoA competitor selective for the p300 HAT 
domain (Ki ~ 400 nM).  More importantly, C646 was shown to suppress histone 
H3 and H4 acetylation in mouse fibroblasts at low micromolar concentrations  
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without significant cytotoxicity.  In contrast, the garcinol-derivative LTK14 has a Ki 
of ~5 µM with an IC50 of ~5-7 µM, indicating a very small index for probing the 
effects of HAT inhibition (55).  We therefore chose to use C646 as a way to 
explore the role of p300 HAT activity in NANOG regulation. 
 
NCCIT cells were first treated with C646 at increasing concentrations to 
determine the effects on cellular viability (Fig. 3.8B).  C646 displayed a GI50 of 
~50 µM over 48 h and was well tolerated by the cells at lower concentrations, 
consistent with other reports (57). We chose to test the effects of C646 at both 10 
µM and 40 µM initially to try and maximize the effects of p300 inhibition.  These 
concentrations are in line with other reports of cell-based experiments using 
C646 (57).  The large difference between the in vitro Ki (400 nM) and cellular 
assay (low micromolar) concentrations could be due to a variety of effects 
including cellular permeability, compound stability in cells, and sequestration by 
other cellular proteins.  We therefore sought to verify that C646 could decrease 
p300 HAT in NANOG-expressing cells.  To do this, we tested the ability of C646 
to block histone deacetylase inhibitor-driven enrichments in histone H3 
acetylation (H3Kac), a known marker for p300 HAT activity.  NCCIT cells treated 
with C646 alone showed significantly reduced levels of H3Kac over basal 
acetylation levels (Fig. 3.8C), while trichostatin A (TSA) treatment greatly 
increased H3Kac levels as expected.  Impressively, pretreatment with C646 was 
able to dose-dependently block TSA-induced H3Kac enrichment, indicating that 
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C646 can potently inhibit p300 HAT activity in NCCIT cells at sub-GI50 
concentrations and may therefore be useful as a chemical probe. 
 
Next we tested the effects of C646 on NANOG expression levels in NCCIT cells.  
An initial titration experiment indicated that C646 reduced NANOG mRNA levels 
by ~50% at both 20 µM and 40 µM concentrations after 24 h (data not shown).  
We chose to conduct future experiments at 20 µM to further avoid potential 
complications from viability effects.  We also observed in time course 
experiments that C646 exhibited greater effects at earlier time points, possibly 
indicating that the compound is metabolized over time.  When C646 was 
administered to NCCIT cells for 6 h at 20 µM, NANOG mRNA levels were still 
significantly suppressed by ~2-3-fold compared to vehicle treated cells (Fig. 
3.8D).  Furthermore, C646 had no effects on other ESC-related genes such as 
KLF4 (Fig. 3.8D), suggesting that p300 HAT activity is acutely necessary for 
maintaining NANOG transcription, and that NANOG mRNA may have a brief 
half-life in the cell. 
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We next examined the effect of p300 HAT inhibition on histone acetylation and 
protein occupancy at the NANOG promoter to determine how C646 could be 
downregulating NANOG expression.  In chromatin occupancy (ChIP) assays, 6 h 
treatment with C646 significantly reduced H3Kac levels at the NANOG promoter 
by ~50% (Fig. 3.9A).  At the same time, p300 occupancy was not altered, 
indicating that p300 HAT activity is not required for coactivator recruitment, but is 
essential in maintaining high levels of histone acetylation.  In contrast, when we 
examined an intragenic region within the NANOG gene body, we failed to detect 
significant levels of either H3Kac or p300 (Fig. 3.9B), consistent with other 
studies finding that p300 predominantly localizes to the promoter region of target 
genes (58).  Taken together, these results suggest that p300 HAT activity is 
essential for acetylating histones in the NANOG promoter, but that HAT activity is 
a secondary event to initial p300 recruitment.  
 
3.5. Conclusions and Future Directions 
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3.5.1.The role of the CH1 domain and its potential interactions 
Our results indicate that both the CH1 domain and the catalytic HAT domain of 
p300 are both required for coactivator function and transcriptional activation of 
NANOG in some human cancer cell lines.  Deletion or mutation of the CH1 
domain significantly impairs the ability of p300 to drive expression from the 
NANOG promoter (Fig. 3.6-7).  Given the role of the CH1 domain in binding 
DNA-bound activators, these results would suggest that CH1 is likely acting as 
an initial interface for recruiting p300 to the NANOG promoter.  The observation 
that deletion of other activator-binding domains has little to no impact on p300 
coactivator function (Fig. 3.5-6) indicates that the CH1 domain may be the major 
or only domain involved in activator recognition and p300 localization. 
 
The CH1 domain is known to interact with a variety of transcriptional activators, 
including p53, HIF1a, and ETS1 (43, 59).  Intriguingly, the Kruppel-like factor 
(KLFs) family of activators have also been reported to bind CH1 in vitro (60).  
Furthermore, KLFs have been shown to bind to the CH3 domain of p300 (61) 
and are functionally dependent upon p300 for transcriptional activity (Evans et al. 
2007).  Our promoter analysis data indicate that KLF factors, in particular KLF4, 
are essential for NANOG promoter activity (Chapter 2). Thus, we speculate that 
KLFs may bind the CH1 domain of p300 and thereby recruit the coactivator to the 
DNA to initiate transcription.  It is worth noting that no study thus far has explicitly 
tested for a KLF4-CH1 interaction.  We therefore attempted to detect a KLF4-
CH1 domain interaction. 
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To do so, HA-tagged KLF4 and Myc-tagged CH1 were overexpressed in 293T 
cells and immunoprecipitated to pull down potential binding partners.  
Unfortunately, no interaction was detected between the two (Fig. 3.10).  
Activator-coactivator interactions tend to be modest in affinity, and the KLF1-CH1 
interaction has a reported Kd of ~3.0 µM (60).  It is possible that a KLF4-CH1 
complex could be too weak to survive the lysis and buffer conditions during co-
immunoprecipitation, and we therefore cannot rule out the possibility of a KLF4-
CH1 interaction.  Other techniques such as isothermal calorimetry or 
fluorescence polarization could more definitively address this question. 
 
 
An important and intriguing observation were the differential responses of 
HNSCC and NCCIT cells to p300/CH1 domain overexpression.   In HNSCC cells, 
p300/CH1 was sufficient to inhibit NANOG transcriptional activity, tumorsphere 
formation, and even block xenograft growth (Fig. 3.4D).  However, in NCCIT 
cells, p300/CH1 overexpression had no effect on endogenous gene expression 
	     77 
(Fig. 3.3C).  It is currently unclear why these two cell lines display different 
effects, however there are notable differences in the experiments.  For the 
HNSCC experiments, we generated stable p300/CH1-expressing cell lines, 
ensuring that all cells in the culture were expressing the domain.  This helps to 
normalize the population by excluding potential contributions from untransfected 
cels, as well as maintaining p300/CH1 expression over the course of multiple 
(>7) passages.  Thus, the effects observed are relatively long-term compared to 
the transient transfections done with NCCIT cells.  The short-term experiments 
also underwent a selection step, however this involved the cotransfection of a 
secondary selectable plasmid.  Therefore, we cannot ensure that all surviving 
cells were cotransfected and thus also expressing p300/CH1.  Furthermore, the 
brief (2-3 day) timecourse of these experiments may mask delays in response 
due to factors like mRNA/protein turnover rates. 
 
An additional possibility for why p300/CH1 overexpression showed variable 
effects could be that HNSCC and NCCIT cells in fact have differential 
requirements for the CH1 domain.  For example, HNSCC cells could express 
relatively lower levels of p300, and thus would be more sensitive to forced 
expression of the dominant-negative form of CH1.  Alternatively, the CH1 domain 
may be interacting with different partners in HNSCC vs. NCCIT cells, and this 
could in turn result in a different outcome.    What these differences might be, 
and why they would result in a different effect, are not currently clear and would 
require further experiments to clarify how broadly the p300/CH1 construct is 
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expressed in the cellular populations, its lifespan and localization within the cell, 
and most challengingly, the potential differences in interactions between the cell 
types.  Such insights would provide immense insights into the potential 
differences in NANOG regulatory requirements between cell lines, but are 
currently outside the scope of the work presented in this thesis.  Instead, we 
chose to focus on how the apparent conserved requirement for the CH1 domain 
could be utilized for modulating NANOG expression. 
 
3.5.2. Small molecule inhibitors of the CH1 domain 
The observation that the CH1 domain is crucial for p300 activity at the NANOG 
promoter suggests that small molecule inhibitors of the CH1 domain could be 
effective at suppressing NANOG expression in cancer cells.  There are several 
reported inhibitors of CH1 domain interactions, including the natural product 
chetomin and related epipolythiodiketopiperazines that disrupt CH1 folding by 
chelating zinc (62-64), as well as peptidomimetics that compete with activator 
binding (65).  To test the hypothesis that small molecule inhibitors of CH1 could 
block NANOG expression, we treated cells with both chetomin and a hydrogen-
bond surrogate peptide designed to mimic HIF-1α (65).  Unfortunately, neither 
compound downregulated NANOG expression levels (data not shown), and 
chetomin showed high cytotoxicity consistent with other reports (63).  However, 
as part of follow up assays, neither compound was able to block DFO-induced 
VEGF expression in positive control experiments, indicating that we were unable 
to reproduce biological activity with these compounds in our cell models.  While 
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disappointing, these results do not rule out the potential for CH1 domain 
inhibitors in blocking NANOG expression. 
 
There are a number of possible reasons why these small molecules were not 
active.  For the hydrogen-bond surrogate peptide, the lack of activity could likely 
be explained by poor membrane permeability.  Further experiments using a 
fluorophore-labeled peptide could resolve this question.  Additionally, the peptide 
is designed to resemble the activator HIF1α and bind in the same location on 
CH1.  However, our mutagenesis studies indicate that there is likely a broad 
interaction interface, and the peptide may either be too small to outcompete such 
a large interaction, or binding in a noncompetitive site and thus unable to block 
the interaction.  No structures have been reported for a KLF-CH1 interaction, so 
we do not know at this time whether there is potential overlap between the HIF-
1α peptide and KLF binding sites.  Future binding assays with HIF-1a and KLF 
peptides could explore their relative binding modes and determine whether a 
HIF-1α-inspired peptide could be an effective inhibitor of NANOG transcription.  
Alternatively, the peptidomimetic strategy could be applied to the KLF activation 
domain as well, however it has yet to be determined if KLF factors adopt an 
alpha-helical conformation upon binding to the CH1 domain (44). 
 
As for chetomin, the high cytotoxicity seen is unsurprising given its promiscuous 
zinc-leaching ability.  A large number of proteins in the cells rely on zinc as either 
a catalytic or structural component, and disruption of zinc homeostatsis by 
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chetomin likely severely stresses the cell.  Other analogues like ETP-2 (63) are 
less toxic and may offer greater selectivity in future experiments.  However, ETP-
2 still utilizes the same mechanism of action and would likely disrupt similar 
domains such as the CH3 domain. As a result, chetomin and ETP-2 may not be 
well suited for use as selective chemical probes of p300/CH1-domain function in 
NANOG expression.  
 
The difficulties encountered with the small molecule studies highlight the need for 
a broader tool set for probing the p300/CH1 domain.  Recently, the small 
molecules menadione and ethacrynic acid were reported to be sub-micromolar 
inhibitors of the HIF1α-CH1 interaction (66).  These compounds do not appear to 
chelate metal ions and may therefore inhibit CH1 domain interactions via other 
mechanisms, suggesting they may be potentially useful in future attempts to 
probe CH1 function.  However, menadione and ethacrynic acid, like chetomin 
and the hydrogen-bond surrogates, all were designed to inhibit the HIF-1α 
interaction.  Thus, there is still a need for a more diverse catalogue of inhibitors 
targeting other sites on the CH1 domain.  Developing such inhibitors would 
provide a comprehensive toolkit for probing a variety of CH1 interactions and 
could be applied to a large number of studies beyond just those described here. 
 
3.5.3. p300 HAT activity is required, but not histone-mediated 
In addition to the CH1 domain, we also identified an essential role for p300 HAT 
activity during NANOG transcription.  Inhibition using the p300-selective C646 
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results in significantly decreased expression levels of NANOG (Fig. 3.8).  This 
decrease in NANOG mRNA coincides with a depletion of H3Kac at the NANOG 
promoter, but not within the gene body of NANOG, indicating that p300 HAT 
activity is confined to the promoter region.  Furthermore, C646 does not alter 
p300 occupancy, suggesting that p300 recruitment is not dependent upon 
histone recognition by the HAT domain.  Taken together, these results would 
suggest that: i) p300 HAT activity is required at a later step during transcriptional 
activation, and ii) histone acetylation by p300 is necessary for maintaining high 
levels of NANOG expression. 
 
To explore this latter point, we tested the effects that histone deacetylase 
inhibitors (HDACIs) have on NANOG expression.  HDACIs prevent the removal 
of acetyl groups from histone tails and thereby significantly increase histone 
acetylation.  We reasoned that, if p300-mediated histone acetylation is essential 
for sustained NANOG expression, HDACIs would either enhance or have little 
effect on NANOG levels.  Since several HDACIs are FDA-approved as 
anticancer drugs, such an observation could have significant clinical implications 
for eliminating cancer-initiating cells during chemotherapy.  
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When the HDACI trichostatin A (TSA)(Fig. 3.11A) was applied to NCCIT cells 
though, NANOG mRNA levels were significantly reduced after just 6 h (Fig. 
3.11B).  Furthermore, TSA strongly enriched for H3Kac levels both globally (Fig. 
3.11B-C), and at the NANOG promoter (Fig. 3.11D).  Similar results were 
observed with the HDACIs SAHA and the class II-selective PD106 (data not 
shown).  These results would suggest that TSA inhibits NANOG expression even 
though histone acetylation levels increase, in contrast to our initial hypothesis. 
One possible explanation could be that histone hyperacetylation disrupts 
expression at the NANOG locus, such as through excessive chromatin relaxation 
and spurious transcriptional initiation.  Alternatively, if histone acetylation is not a 
key determinant in NANOG transcription but p300 HAT activity is required, then 
p300 may be acetylating a non-histone substrate and that acetylated protein is 
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required for maintaining NANOG mRNA levels.  The possibility of a non-histone 
substrate was intriguing and we chose to first explore this potential mechanism. 
 
p300 has a number of non-histone substrates, including transcriptional activators.  
Interestingly, p300 is known to acetylate KLF4 at K225 and K229, and p300-
mediated acetylation is essential for KLF4 transcriptional potential (48). Given 
our earlier data indicating KLF4 is an essential activator of NANOG (Chapter 2), 
we sought to determine if p300-mediated KLF4 acetylation was required for 
NANOG expression.  However, when the acetylation sites were mutated to 
arginine (K225R and K229R) no significant difference in activation potential was 
observed (Fig. 3.12A,B), suggesting that KLF4 may not be the necessary 
substrate of p300 HAT activity.  Identifying this protein would likely require 
unbiased mass spectrometry screening to look for changes in acetylated proteins 
following C646 treatment (67). 
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3.5.4. A broader model of NANOG transcriptional activation 
Take together, our results provide the first systematic interrogation of p300 
functions for NANOG expression in cancer cells.  When combined with our 
promoter analysis and activator identification data, we can begin to assemble a 
more comprehensive model for how transcriptional initiation occurs at the 
NANOG promoter (Fig. 3.13).  Based on our results, we propose that the 
transcriptional activator KLF4, or related KLF family members, bind to the 
proximal promoter region just upstream of the transcriptional start site.  Once 
localized to the DNA, KLF4 activates transcription of NANOG.  KLF4, like many 
activators, may recruit coactivators like p300.  p300 is localized to the NANOG 
promoter through an as yet unknown series of interactions, but one possible 
explanation would be via CH1 domain interactions.  These interactions are not 
well characterized yet, but it would appear to be dependent upon the structural 
integrity of the entire CH1 domain, and thus the proteins may form extensive 
contacts with one another. 
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Once localized to the NANOG promoter, the p300 HAT domain will then 
acetylate histone N-terminal tails.  Histone acetylation is associated with a more 
relaxed chromatin structure and may thereby facilitate transcription.  However, 
histone acetylation by p300 is not the sole factor since NANOG can be 
downregulated even when H3Kac levels are high.  Therefore, p300 may also be 
acetylating some other protein(s) that are also essential for full transcriptional 
activity, but for now remain unidentified.  These unknown proteins must operate 
after p300 recruitment since p300 promoter occupancy is not sufficient to 
stimulate transcription.  It may be that p300 HAT activity is required to stabilize a 
larger “enhanceosome”-like transcriptional complex (68).  p300 is known to 
participate in large multiprotein complexes (69-70), and it would be further 
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illuminating to identify other transcriptional cofactors involved in NANOG 
regulation. Already, the results shown here reveal two potential opportunities for 
modulating NANOG levels just by targeting the p300 coactivator: i) blocking CH1 
domain interactions and ii) inhibiting p300 HAT activity. Such information could 
lead to the design of more selective combinatorial strategies to inhibit NANOG 
expression in cancer, or modulate its expression in cellular reprogramming 
efforts and regenerative medicine. 
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3.7. Materials and Methods 
Cell lines 
NCCIT, HeLa, and 293T cells were purchased from ATCC.  NCCIT cells were 
grown in RPMI media 1640 (Life Technologies, 11875) supplemented with 10% 
fetal bovine serum (Atlanta Biologicals, S11195) in a 37 ºC incubator with 5% 
CO2.  All other cell lines were cultured in Dulbecco’s Modified Eage Medium 
(DMEM) (Invitrogen, 11965) supplemented with 10% fetal bovine serum. 
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For C646 and TSA treatments, compounds were dissolved in DMSO and 
administered to the cells at varying concentrations.  C646 appeared to have a 
short half-life in the cells as indicated by a cell-dependent loss of color.  
Therefore, fresh compound was applied every 24 h for longer time courses.  
Changes in cellular viability were measured using the WST-1 assay and data 
was normalized against the DMSO vehicle control. 
 
For gene expression experiments, cellular RNA was harvested using the RNeasy 
kit (Qiagen).  1 µg RNA was used as a template for reverse transcriptase (iScript 
cDNA Synthesis Kit, Bio-Rad) following the manufacturer’s instructions.  1 µl 
cDNA was used for quantitative PCR reactions using Taqman probes for 
NANOG, KLF4, and GAPDH as an internal control.  Data was normalized using 
the ∆∆Ct method against GAPDH levels. 
 
Cell proliferation was assessed using the MTT reagent (Roche Molecular 
Biochemicals, Nutley, NJ, USA) to detect metabolic active cells. Absorbance was 
measured at 570nm in the Spectra Max 190 ELISA reader (Molecular Devices, 
Sunnyvale, CA, USA) after overnight incubation. For clonogenic survival, 300 
cells per well were plated in complete growth media and allowed to grow until 
visible colonies were formed (14 days). Cell colonies were fixed with 10% cold 
methanol, stained with 0.1% crystal violet in 20% methanol, washed and air 
dried. The soft agar assay was performed in 35mm plates containing two layers 
of Agar (Invitrogen). The bottom layer consisted of 0.6% agar in 1.5 ml of DMEM 
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with 10% FBS. Cells were dissociated and placed (5 × 103/well) in the top layer 
containing 0.3% agar in the same medium as the bottom. Cells were cultured for 
three weeks and colonies were photographed under a microscope and measured 
NIS-Elements software (Nikon, Melville, NY, USA). Colonies with diameters 
larger than 80 µm were counted. 
 
Tumorsphere formation 
Cells were collected and seeded in a serum-free defined medium consisting of 
keratinocyte serum-free medium supplemented with epidermal growth factor, 
basic fibroblast growth factor, insulin and hydrocortisone in low-attachment plates 
(Corning Incorporated, Corning, NY, USA) for tumorspheres. Tumorsphere-
formation efficiency was calculated as the number of tumorspheres (≥50 µm in 
diameter) formed in 7 days divided by the original number of cells seeded. 
Tumorsphere diameter was measured using NIS-Elements software. 
 
Tumor incidence and growth in athymic nude mice 
UMSCC47/CH1 cells were suspended in 50:50 Dulbecco’s modified Eagle’s 
Medium : Matrigel and implanted subcutaneously into the left and right flanks of 
6-week-old athymic nude mice (eight mice/group), respectively. After 3 weeks, 
tumors were measured once a week using a digital caliper, and tumor volumes 
were calculated using the formula d1 x d2 x d3 x 0.5236, where ‘d’ represents the 
three orthogonal diameters. Tumor growth and incidence were monitored for 49 
days following tumor cell implantation. 
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Chromatin immunoprecipitation assays 
ChIP assays were performed on >90% confluent cells in 10-cm plates using the 
Abcam ChIP (ab-500) protocol..  Briefly, cells were dissociated by trypsin digest 
and resuspended in media + 10% FBS before counting.  10 x 106 cells were then 
pelleted by centrifugation and then washed with chilled PBS.  Cells were then 
fixed with 1% formaldehyde for 10 min at room temperature before quenching 
with 1.25 M glycine.  The fixed cells were washed with chilled PBS and 
resuspended in lysis buffer.  Samples were then pelleted to collect the fixed 
chromatin.  Mild sonication was carried out to yield sheared chromatin averaging 
~500 bp in size.  Immunoprecipitations were conducted on the sheared 
chromatin using anti-histone H3 (Abcam, ab1791), anti-p300 (Santa Cruz, sc-584 
X), anti-acetylated histone H3 antibody (Millipore, 06-599), or Protein A beads 
alone as a negative control.  The recovered DNA was used as a template for 
qPCR reactions using SYBR Green (Applied Biosystems, 4309155) according to 
the manufacturer’s instructions. 
 
Plasmids and cloning 
The p300 and KLF4 plasmids were originally purchased from Addgene (pCMVb-
p300, plasmid 10717; pcDNA3.1-HA-KLF4 FL, plasmid 34593).  Deletions and 
point mutations were then introduced using site-directed mutagenesis.  Mutants 
were validated by DNA sequencing. 
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Transfections 
NCCIT cells were transfected using OptiMEM media (Invitrogen) and 
Lipofectamine LTX (Invitrogen) according to an optimized protocol.  Briefly, 
DNA•liposome complexes were formed in OptiMEM by sequentially adding DNA, 
PLUS reagent, and LTX and incubating for 30 min at room temperature.  Four 
volumes of RPMI (10% FBS) was then added to the transfection mix before 
applying to the cells.  The cells were incubated with the transfection mix for 24 h 
before switching media and grown for an addition 24 h. 
 
Luciferase assays 
10,000 cells were plated in 96-well format with 100 µl media + 10% FBS.  After 
overnight incubation, the media was replaced with transfection mix: 100 µL 
media with 5 ng/ml Renilla luciferase plasmid (pRLSV40) and 395 ng/ml firefly 
luciferase plasmid.  After 48 h incubation, luciferase activity is measured on a 
Berthold luminometer with firefly substrate from the Dual-Luciferase Assay 
Reporter System (Promega, E1980). 
 
Co-immunoprecipitation assays 
293T cells were transiently transfected by lipofectamine with HA-KLF4 and 
p300/CH1-Myc or empty vector for 3 hr according to the manufacturer’s protocol.  
After transfection, cells were incubated overnight in DMEM (+10% FBS).  Cells 
were then washed with media followed by three washes with 10 ml ice cold PBS 
and collected by scraping and centrifugation.  A modified RIPA buffer (1% NP-40, 
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0.1% SDS, 0.5% Na deoxycholate, and protease inhibitor cocktail) at a volume of 
400 µl/10 cm dish was then used to lyse the cells.  The cellular extracts were 
divided into fractions and aliquots were taken to serve as input controls.  Further 
aliquots were taken and immunoprecipitated using anti-Myc (Santa Cruz, sc-40), 
anti-hemagglutinin (sc-7392), and anti-IgG (sc-2025, sc-2027) antibodies.  Sixty 
microliters of a 50% protein G-sepharose solution were then added and the 
incubation continued at 4 ºC for 1 h.  The beads were collected by centrifugation 
and washed three times with 1 ml modified RIPA buffer before being 
resuspended in sample buffer for electrophoresis.  
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Chapter 4 
Expanding the toolkit for targeting cancer-initiating cells through chemical 
biology 
 
4.1. Abstract 
Cancer-initiating cells (CICs) are an unstable and poorly understood 
subpopulation of cancer cells that also represent an incredible opportunity for 
new therapeutic developments.  New technologies and tools are necessary to 
overcome some of the inherent challenges associated with studying CICs in vitro 
in order to deliver on the promise of CIC-targeting therapies.  Here we discuss 
important areas of CIC biology that are in need of new tools and describe ways 
chemical tools could address those needs. 
 
4.2. Challenges involved in studying cancer-initiating cells 
The model of cancer-initiating cells (CICs) in cancer biology has generated a 
tremendous amount of new theories into how tumors originate, respond to 
therapeutic strategies, and how to effectively combat the disease (1-3).  These 
theories will require rigorous testing in order to usher in the next wave of medical 
advances.  However, CICs possess multiple challenges for their study.  First, 
CICs are frequently found in heterogeneous cell populations (1, 4) and therefore 
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require methods to identify and isolate CICs from non-CICs (5).  Second, CICs 
are multipotent by definition and are capable of spontaneous differentiation.  This 
intrinsic instability makes CICs difficult to control and maintain.  Lastly, very little 
is known about how CICs are controlled in terms of both extra- and intracellular 
regulatory programs.  This information is essential for understanding the 
underpinning biology of CICs, as well as directing future drug discovery 
strategies. 
 
In order to address the challenges outlined above, CIC biology requires new 
tools for probing the inner workings of a rare, unstable cell type.  Chemical 
approaches and small molecules have provided unique ways of observing and 
manipulating biological systems, and as such are poised to provide the 
necessary tools for studying CICs. This chapter identifies areas in CIC biology 
that would greatly benefit from new techniques, as well as possible strategies for 
providing such tools.  
 
4.3. Protein-protein interactions in CIC-regulatory networks 
4.3.1. Strategies for examining the global interaction networks 
The unique transcriptional and signaling networks that define CICs are among 
the most intriguing and sought after targets in CIC biology.  Such interaction 
networks feature prominently in nearly every biological process, but remain 
difficult to study due to their complexity.  For example, transcriptional networks 
regulating self-renewal can involve dozens of proteins driving the expression, or 
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suppression, of hundreds of genes (6-8).  To further complicate the network, 
most of these proteins can engage in multiple protein-protein interactions (PPIs).  
As a result, identifying the key interactions can be challenging due to the sheer 
complexity of the networks. 
 
Other stem cell model systems have tackled questions about protein-protein and 
transcriptional networks through the use of affinity-based capture methods in 
combination with mass spectrometry to identify interacting proteins.  For 
instance, Wang et al. (8) described an interaction network for the transcriptional 
activators Oct4 and Nanog in mouse embryonic stem cells (ESCs).  To do this, 
the ESCs were made to express low levels of exogenous Oct4 and Nanog that 
bore an N-terminal peptide substrate that could be biotinylated in cellulo.  The 
biotinylated activators could then be purified along with proteins that likely 
interact with Oct4 and Nanong under physiological conditions.  Mass 
spectrometry-based identification of the associated proteins generated a map of 
PPIs for Oct4 and Nanog in ESCs, and the network overall was found to be 
significantly enriched in proteins that regulate ESC identity.  Moreover, the 
network members also appeared to be colocalize at ESC-specific genes in global 
chromatin immunoprecipitation (ChIP) studies (7, 9), suggesting the Oct4/Nanog-
PPI network is functionally cooperating to regulate ESC pluripotency and self-
renewal.  
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CICs can express many of the same proteins as ESCs (e.g. NANOG, OCT4) (10-
12), yet it is unclear whether the same PPIs occur.  While CICs and stem cells 
may share features like self-renewal, the differences in cellular context can 
translate into very different sets of expressed proteins and regulatory signals that 
can greatly alter the types of interactions NANOG and OCT4 engage in.  For 
example, NANOG has been reported to be phosphorylated by protein kinase Cε 
(PKCε) (13, 14).  PKCε is frequently mutated or overexpressed in cancer leading 
to elevated kinase activity (15, 16) and these altered phosphorylation levels could 
easily affect NANOG interactions (17).  Therefore, due to concerns about the 
potential differences between cell types, global PPI and ChIP studies should be 
revisited in CICs to determine just how much overlap still exists in the PPI 
partners for proteins of interest in CIC and other stem cell models.   
 
4.3.2. Strategies for examining local interactions 
While unbiased and informative, global studies like those described above 
(Chapter 4.3.1) suffer from lack of information about the specific PPIs.  Global, 
low-resolution pull-down experiments only identify the presence of an interaction 
between proteins; these interactions could be direct or indirect, mono- or 
multivalent, low- or high-affinity, etc.  These sorts of details need to be 
determined in order to design efficient probes of PPIs in CICs, especially for 
multifunctional proteins like p300. 
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The respective functions of p300 have been studied in other stem cell systems 
using mutagenesis strategies (18).  Specifically, mouse hematopoietic stem cells  
(HSCs) expressing an allelic series of p300 domain mutants revealed that the 
CH1 and KIX domains are necessary for HSC engraftment in the bone marrow 
niche and for proper hematopoietic differentiation (18).  Deletion of other 
domains, or mutational inactivation of the histone acetyltransferase (HAT) 
domain had little effect on hematopoiesis. 
 
Similarly, the work presented in this thesis utilized a series of complementary 
mutational and small molecule antagonists to parse out the relevant functions of 
p300 during NANOG expression in cancer cells (Chapter 2.3-4, 3.3-4).  Our 
results indicate that the CH1 and HAT domains are both essential for NANOG 
expression and therefore may be strong candidates for future inhibition 
strategies.  Importantly, p300 can be viewed as a model for other multidomain 
proteins.  Therefore, the strategies described here to dissect multifunctional 
proteins can be applied to other targets in CIC biology. 
 
 
4.4. CIC cultivation and external interactions 
4.4.1. Engineering microenvironments for CICs in vitro 
One of the main challenges in the study and clinical application of CICs is that 
although these cells are multipotent and highly self-renewing in vivo, they are 
difficult to maintain and expand in vitro in homogeneous populations.  This can 
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complicate experiments since any change or effect must be evaluated within a 
mixed sample of cells.  Several groups have circumvented this hurdle by 
generating their own in vitro model for CICs.  Gupta et al. (4) induced an artificial 
epithelial-mesenchymal transition (EMT) state to create a more CIC-like cell 
state.  Similarly, Sachlos et al. (19) used a tumorigenic variant of normal stem 
cells to form a more stable, uniform cell population.  These studies have the 
important caveat that the resulting cultures only resemble CICs; they are not, in 
fact, CICs identified from tumors.  However, the results from such artificial 
systems indicate that stable CIC cultures could greatly improve efforts to study 
CICs and aid drug discovery.  The challenge for the field going forward, 
therefore, is developing methods for isolating, expanding, and cultivating stable 
CIC populations in vitro. 
 
One of the most promising techniques for in vitro CIC cultivation is through the 
use of defined culture conditions.  Indeed, defined soluble factors such as bFGF, 
EGF, and insulin are already in use for standard tumorsphere formation assays 
that measure clonogenicity and self-renewal in vitro.  However, soluble signals 
are only part of the total inputs a CIC receives from the external environment that 
support CIC maintenance.  Another, perhaps more important input comes from 
the extracellular matrix (ECM). The ECM consists of a complex mixture of 
proteins, proteoglycans, and polysaccharides that provide adhesive interactions 
essential for stem cell- and CIC-maintenance (20, 21).  The ECM helps to define 
a supportive microenvironment and this microenvironment can, in theory, be 
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recreated in vitro provided key factors are identified.  Most substrata currently 
used in cancer cell line and CIC cultures are comprised of mixtures of 
extracellular matrix proteins derived from animal sources, such as collagen or 
Matrigel (22, 23).  As a result, these products often suffer from variability 
between batches and present issues with reproducibility.  Additionally, the 
complex mixture of proteins and signaling factors present in these substrates 
make it more difficult to understand and control the cell-substrate interactions.  
The key to engineering a suitable CIC niche in vitro therefore resides in first 
identifying the components that precisely control CIC identity. 
 
To the best of our knowledge, no groups have yet defined an in vitro niche for 
CICs, but recent advances in artificial microenvironments for other stem cells can 
provide a template for future studies.  For example, Villa-Diaz et al. (24) reported 
that acrylate polymers could support ES cell cultures in defined media, opening 
up possibilities for future experiments to examine physicochemical properties 
necessary for maintaining a stem cell niche including ionic charge and 
mechanical stiffness (25).  The relative ease with which these polymeric 
substrates can be synthesized and modified would not only facilitate the study of 
ES cell-niche factors, but could also be transferred to additional cell types 
including CICs. 
 
While polymer-based substrates can support stem cell cultivation, they may not 
reveal new binding interactions or requirements supplied for the niche due to lack 
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of identified receptors for most polymers.  In order to explore interactions that 
better reflect the endogenous ECM-stem cell interactions, Kiessling and 
colleagues (26, 27) selectively cultivated pluripotent embryonic stem (ES) cells 
on defined peptide substrate monolayers. The authors chose to synthesize an 
array of laminin-derived peptides presented on a gold substratum by coupling the 
variable peptide components to a self-assembling alkanethiol moiety (26).  These 
monolayers could be spatially patterned to facilitate screening for peptides 
capable of supporting ES cell adherence and growth in the absence of MEF 
feeder layers used in typical ES cell culture.  The peptides identified in this 
screen were able to maintain ES cell pluripotency over the course of the screen 
(5-7 d) and, impressively, were comparable to Matrigel in terms of supporting ES 
cell proliferation.  Furthermore, the active peptides help to identify critical 
domains and regions within the large laminin ECM proteins that mediate ES cell 
maintenance.  In addition to laminin-derived peptides, the Kiessling group 
demonstrated that heparin-binding peptides were also capable of supporting 
long-term in vitro ES cell cultivation (27).   
 
Taken together, these studies provide proof-of-principle that multipotent stem 
cells can be maintained and manipulated in vitro using defined 
microenvironments.  ES cells have been the most popular objects of study with 
these experiments, but similar artificial niches have been described for a variety 
of adult stem cell types (reviewed in ref. 28).  As a result, it is reasonable to 
predict that the strategies employed in studying stem cell microenvironments 
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could be applied to CICs, both to aid cultivation and to generate new insights into 
their behavior in vivo. 
 
4.4.2. Screening for substrates for CICs in vitro 
The development of a supportive CIC-substrate, such as through the use of 
defined peptide substrates similar to the strategies described above, would first 
require screening for matrix molecules (e.g. polymer, peptide, hydrogel, etc.) 
suitable for maintaining CICs.  Fortunately, the synthesis of these molecules is 
fairly straightforward and amenable to modification and diversification, allowing 
potentially large libraries of candidate molecules to be screened.  Such screens 
would require extensive controls in place to ensure that the cells growing on the 
“hit” substrates are: i) identified or putative CICs, ii) viable and propagating, and 
iii) multipotent.  This is important since the primary goal of the screen would be to 
distinguish between substrates that support CICs as opposed to allowed 
nonspecific attachment of more differentiated cancer cells.  CICs have a variety 
of markers and/or assays established for measuring these qualities (e.g. ALDH1-
staining, cell-surface markers, etc.) that can be incorporated into screens as 
potential readouts. 
 
A reasonable outline for a CIC-substrate screen, therefore, would begin first with 
the synthesis of a library of potential substrates followed by immobilizing or 
printing the library onto a high throughput-compatible platform such as glass 
slides or multiwall dishes (Fig. 4.1.A-B).  The substrates could then be incubated 
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with dissociated CICs that were isolated through techniques such as CIC 
enrichment assays (e.g. tumorspheres, fluorescence-activated cell sorting)(Fig. 
4.1.B).  A simple counterscreen would be to run a parallel plate using the non- 
 
CIC populations to compare for selective attachment.  After several days, the 
plates could be inspected for potential expansion and staining for CIC markers 
such as CD133 (Fig. 4.1.C-D).  Candidate substrates could then be identified and 
subjected to further rounds of testing and modification to improve the efficiency of 
CIC attachment and propagation. 
 
Identifying reliable and robust substrates for in vitro cultivation would promote 
CIC research across the board by increasing the accessibility to a challenging 
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cell type to study in isolation.  Additionally, knowing what substrates foster CIC 
growth can reveal new information into CIC biology through the identification of 
cell surface receptors and signaling factors responsible for regulating CIC self-
renewal and identity (25). 
 
4.4.3. Substrate platforms in probe and drug discovery screens 
A robust in vitro platform for studying the CIC microenvironment could also open 
up exciting new possibilities for small molecule discovery.  To date, that majority 
of small molecules described as CIC inhibitors target intracellular signaling 
pathways associated with CIC biology (Table 1.1).  However, if essential ECM-
CIC interactions are identified then additional CIC-targeting strategies can be 
pursued, such as through the use of antibodies to mask potential niche sites or 
the development of small molecule ECM-receptor inhibitors to antagonize critical 
extracellular signals.  These molecules could be used to inhibit ongoing niche 
signals and thereby induce CIC differentiation and exhaustion, or act as a 
blockade against CIC engraftment during metastasis.  Consequently, these 
alternative strategies could strongly complement current CIC probe and drug 
discovery methods. 
 
4.5. CIC identification 
Since CICs are often a minor subpopulation within the heterogeneous population 
of cells present in a tumor, a major challenge to CIC research remains the ability 
to identify and separate CICs from non-CICs.  CIC identification relies upon two 
	     108 
categories of defining properties: CIC-specific phenotypes and CIC-specific 
markers.  CIC-specific phenotypes such as self-renewal and multipotency are 
assay-dependent and rely on distinguishing features like CIC self-renewal in 
tumorsphere assays.  These assays do not always allow for prospective 
identification of CICs, but benefit from working with viable cells. 
 
On the other hand, CIC-specific markers such as uniquely expressed proteins 
permit prospective CIC identification, but may compromise viability. Conjugated 
antibodies are the most frequently used method for labeling CICs thanks to their 
sensitivity and potential selectivity.  However, unless the CICs are permeabilized, 
antibodies are unable to penetrate the cell membrane and label intracellular 
markers.  Therefore, antibody-based identification of viable CICs is restricted to 
cell-surface proteins such as CD44 and CD133 (3).  Cell-surface markers are 
often only correlated with CICs and single labels are often not sufficient to 
accurately identify the CIC subpopulation (29, 30).  Thus, additional markers are 
desirable for high-confidence CIC identification. 
 
Intracellular markers can provide a more reliable indicator of CIC-associated 
processes.  For example, transcription factors such as OCT4 and NANOG 
regulate self-renewal in CICs and their presence is strongly associated with CIC 
identity (31).  Enzymatic markers such as aldehyde dehydrogenase 1 (ALDH1) 
are also valuable intracellular markers of CICs in a variety of cancer types (3, 32, 
33).  ALDH1 is believed to act in CICs as a cytoprotective enzyme that detoxifies 
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harmful agents and thereby helps to maintain CIC identity in the presence of 
stress- or differentiating-inducing signals.  ALDH1 activity in particular can be 
determined within living cells and is often used to sort viable CICs in the absence 
of well-defined cell surface markers (3).  ALDH1 enzymatic activity can be 
measured using the substrate BODIPY-aminoacetaldehyde that is converted into 
a negatively charged, fluorescent dye and retained in cells expressing ALDH1.  
This assay can be used in heterogeneous cell populations, and as a result is a 
very popular method for quantifying CIC frequencies by flow cytometry as well as 
for CIC isolation by fluorescence-activated cell sorting (FACS). 
 
Unfortunately, there are relatively few enzymatic markers available for CIC-
labeling besides ALDH1-based assays.  ALDH1 is not a universal marker for 
CICs, so there is a pressing need for more activity-based assays to label CICs.  
Other enzymatic activities linked to CICs include telomerase, the ATP-binding 
cassette membrane transporter ABCG2, and BMI-1 (34, 35).  ABCG2 is a broad 
specificity drug transporter and its activity can be interrogated through the use of 
dye-exclusion assays (36).  Dye-exlcusion assays, like ALHD1-assays, allow 
CICs to be quantified and sorted, but the potential overlap in transporter 
functions and low selectivity in substrates cause these assays to be less 
stringent measurements of CIC properties.  Other enzymes, such as BMI-1, lack 
robust in cellulo assays in order to measure activity in viable cells.  The 
development of new assays and labeling methods for identifying and tracking 
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CICs in mixed cell populations would greatly benefit the study of CICs in general 
by expanding the tools and targets available to researchers. 
 
4.6. Conclusions and Future Directions 
The discovery of CICs as the driving source of many tumors has spurred 
tremendous interest in determining the intra- and extracellular factors that control 
their behavior.  Studying these factors has been challenging due to issues with 
CIC frequency and instability, as well as more general challenges with studying 
complex protein and gene interaction networks.  The works presented in this 
thesis present our efforts towards studying how protein-protein interactions 
involved in transcriptional regulation can be interrogated and reveal new targets 
for future CIC modulation (Chapters 2, 3).  Specifically, we showed how 
multidomain transcriptional coactivators can be identified and manipulated to 
downregulate CIC-associated genes in the absence of information about 
upstream signaling pathways or interaction partners (Chapter 2). We 
demonstrated that the coactivator protein p300 is an essential factor involved in 
NANOG expression in undifferentiated cancer cells (Chapter 2.3).  The regulation 
of NANOG, like many other CIC genes, is currently not well understood in 
pathological contexts.  As a result, our functional analysis of the NANOG 
promoter and its associated activators and coactivators can serve as an example 
of how further CIC genes can be explored (Chapter 2.5). 
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We have also described how individual functions within a multidomain protein like 
p300 can be tested through a series of complementary techniques including 
domain loss- and gain-of-function (Chapter 3.3), mutational analysis (Chapter 
3.3), and small molecule probes (Chapter 3.4, 3.5.2).  These studies allowed us 
to generate a working model for how NANOG is regulated in CICs and other 
undifferentiated cancer cells (Chapter 3.6.4).  Based on this model, we can now 
propose new targets for inhibiting NANOG expression, including protein-protein 
interaction inhibitors for the CH1 domain, and p300-selective histone 
acetyltransferase (HAT) inhibitors.  Similar strategies can be applied to other 
proteins of interest and thereby simplifying some of the challenges associated 
with complex protein-protein interaction networks (Chapter 4.3).  Overall, the 
work described in this thesis reveals new potential targets for modulating 
NANOG expression in cancer cells. Importantly, this work is novel because it is 
the first effort at modulating NANOG expression by targeting the activators and 
coactivators involved in its expression.  The NANOG protein itself is difficult to 
directly target pharmacologically due to poor structural characterization and 
limited information about its binding interactions.  We reasoned that we could 
potentially disrupt NANOG expression and function by targeting the proteins that 
direct NANOG transcription, and demonstrate that the coactivator p300 and its 
CH1 and HAT domains are potential targets for downregulating NANOG.  This 
information can be used to guide the development of new drug and therapeutic 
strategies for NANOG-expressing tumors.  
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Our results using the HAT inhibitor C646 and the histone deacetylase (HDAC) 
inhibitor trichostatin A (TSA) were unexpected and suggest a more complex 
series of interactions between histone modifying proteins, their non-histone 
substrates, and the impact on NANOG expression.  The observation that C646 
inhibits NANOG expression while decreasing histone H3 acetylation (H3Kac) at 
the NANOG promoter, while TSA inhibited NANOG while increasing H3Kac could 
indicate a non-histone substrate for one, or both, HATs and HDACs that helps 
modulate NANOG expression.  We initially tested the possibility that the activator 
KLF4, which is a known p300 substrate, could be one such protein.  However, 
mutation of the p300 acetylation sites within KLF4 had no significant impact on 
KLF4-driven NANOG promoter activity (Fig. 3.12), suggesting that some other 
protein may be the target.  The p300 HAT has a large number of reported 
substrates (6), and it is difficult to predict which known substrates may be 
important for NANOG regulation.  Additionally, there may be a number of as yet 
unidentified p300 HAT substrates that also help regulate NANOG expression.  
One potential future direction for investigating the relative substrates and roles of 
the p300 HAT and HDACs in NANOG expression would be through the use of 
peptide sequencing in C646- and TSA-treated cancer cells to identify 
differentially acetylated proteins.  Such as study could generate a list of 
candidate proteins for further testing.  Additionally, peptide sequencing 
techniques would allow for a closer inspection of the specific histone 
modifications associated with basal NANOG promoter activity, as well as those 
following C646 and TSA treatment.  Our data so far has only examined general 
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H3 lysine acetylation.  Specific histone modifications can carry dramatically 
different effects on transcription, and consequently having a detailed picture of 
how histone modifications change could reveal a more comprehensive picture of 
how p300 is specifically working at the NANOG promoter. 
 
A number of challenges still remain more broadly when studying CICs, including 
issues with their identification, isolation, and cultivation. Several promising 
technologies have emerged for addressing these issues in other challenging cell 
types (Chapter 4.4, 4.5), and tailoring technologies to CICs will undoubtedly 
generate profound advances in the ways cancer is understood, diagnosed, and 
treated in the future. This thesis highlights just some of the many ways chemical 
biologists, with their unique perspectives, can contribute to the field of stem cell 
biology that is always need of better tools. 
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